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ABSTRACT 
 
Objectives: The aims of this study were to: 1) Assess whether naturally induced anti-HPV 
antibodies are associated with subsequent acquisition of genital HPV 6, 11, 16, and 18 infections 
in men, 2) assess the recurrence (redetection) of genital HPV infections of the 9-valent vaccine 
HPV types and investigate factors associated with recurrent infections among men, and 3) assess 
the risk of type-specific sequential acquisition of anal HPV infection following a genital HPV 
infection of the 9-valent vaccine HPV types among men who have sex with women (MSW). 
Methods: 4,123 healthy men were followed every six months (median follow-up time 4.1 years). 
HPV antibodies were measured at baseline using a virus-like particle-based ELISA assay. 
Genital and anal HPV genotypes were detected using the Roche Linear Array assays. Kaplan-
Meier curves and Cox models were developed to assess associations between serum anti-HPV 
antibody and subsequent incident HPV infections. Individual type analyses and grouped analyses 
were carried out to assess type-specific recurrence of the 9-valent vaccine HPV types. Risk of 
sequential anal HPV infection was assessed by examining incident rate ratios (IRR) and adjusted 
hazard ratios (aHR) among men with a prior genital HPV infection compared to men without a 
prior genital HPV infection.  
Results: 1) Significantly higher rates of incident infections were observed for HPV 16 among 
baseline HPV 16 seropositive men (aHR 1.37, 95% CI 1.01-1.86).  Risk of persistent HPV 18 
vii 
 
infection was significantly lower among HPV 18 seropositive men in unadjusted models, but not 
in the adjusted model, while incident and six-month persistent HPV 6 and 11 infections did not 
differ by baseline serostatus. 2) Up to 31% of prior prevalent and 20% of prior incident HPV 
infections recurred over time in individual type analyses. New female sexual partners, frequency 
of sexual intercourse with female partners, and new male sexual partners were associated with 
type-specific recurrence of HPV infections (HPV 6, 16, 31 and 58). In grouped analyses, lifetime 
number of male sexual partners (aOR = 2.40, 95% CI 1.19-4.84) and number of new male sexual 
partners (aOR 2.35, 95% CI 1.16-4.74) were associated with recurrence of HPV infections. 3) In 
individual type analyses, men with a prior HPV 16 genital infection had a significantly higher 
risk of subsequent anal HPV 16 infection (aHR=4.63, 95% CI 1.41-15.23). Significantly higher 
HRs were observed for any of the nine HPV types (aHR= 2.8, 95% CI1.32-5.99), high risk HPV 
types (aHR=2.65, 95% CI 1.26, 5.55) and low risk HPV types (aHR=5.89, 95% CI1.29, 27.01) in 
grouped analyses. 
Conclusion: Baseline seropositive status among men was not associated with a reduction in 
subsequent incident genital HPV 6, 11, and 16 infections, but with a possible protective effect for 
persistent HPV 18 infections. Men are also susceptible to recurrence of type-specific genital 
HPV infections, and recurrence of HPV infection was associated with high-risk sexual behaviors. 
MSW men with prior genital HPV infections are more likely to have a subsequent type-specific 
anal HPV infection than men who did not have prior genital HPV infections. Understanding the 
natural history of HPV infections among men is essential to control HPV associated diseases in 
both men and women.   
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INTRODUCTION  
 
          Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
in men and women in the U.S. (1).  HPV infection causes multiple cancers among men and 
women, including cancers of the cervix, vagina, vulva, penis, oral cavity, head and neck, and 
anal canal (2). The role of HPV in the etiology of cervical cancer has been well documented, and 
vaccines targeting the most common HPV types (HPV 6, 11, 16 and 18) have been in use since 
2006.
3
  Despite low uptake in the U.S., use of HPV vaccination has led to reduced prevalence of 
HPV infections and premalignant conditions (3,4). Until recently, vaccination efforts have been 
largely targeted toward girls and young women.  The natural history of HPV infection among 
men was not studied in detail until recently.  It is now known that HPV infection in men plays an 
important role in the etiology of penile, anal and oropharyngeal cancers.  Furthermore, HPV has 
been shown to be readily transmitted between sexual partners (5).  Thus, an understanding of 
HPV infection in men is critical for preventing HPV-related cancers among both men and 
women.  
          In the proposed study, we plan to examine the association between serum anti-HPV 
antibodies and subsequent incident infections for specific HPV types.  The association between 
anti-HPV antibodies and incident HPV infection has been studied among women, but similar 
associations are not clearly understood among men.  We will also assess recurrent HPV 
infections, factors affecting recurrence for specific HPV types, and genital-anal genotype-
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concordant HPV infections. For the proposed study, we will utilize data from the HPV Infection 
in Men (HIM) Study.  The HIM study is a natural history study of HPV in more than 4,000 
healthy men recruited between 2005-2009 from the U.S., Brazil, and Mexico.  Findings from the 
proposed study will provide valuable information about the natural immune response to HPV, 
recurrent HPV infections and genital-anal genotype-concordant HPV infections will be useful in 
developing prevention strategies, such as HPV vaccination targeting men.  
Background and significance 
          HPV is the most common sexually transmitted infection in the world and was responsible 
for about 527,624 new cervical cancers that occurred worldwide in 2012 (6, 7).  In the U.S., 
32,000 cancer cases in men and women were attributed to HPV in 2009, with the cost for 
prevention and treatment of HPV associated diseases estimated to be $8 billion per year (7, 8).  
An estimated 79 million people are currently infected with HPV, and 14 million individuals 
acquire new HPV infections each year in the U.S. (9).  More than 50% of sexually active 
individuals are infected with one or more types of HPV at some point in their lives (10).  
          HPVs are a group of more than 150 related viruses, with about 40 distinct types that infect 
the genital area (11).  
 
HPV infections can be broadly classified as mucosal (α genus) and 
cutaneous, (including α, β, γ, μ (Mupa), and Nv (Nupa) genera) (12). Alpha (α ) HPV genus 
(including HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 etc) infections can lead to the development of 
various cancers (cervix, vulva, vagina, penis, and oropharynx), as well as benign lesions such as 
genital warts and respiratory papillomatosis (13, 14). HPV 16 and 18 are the most common 
oncogenic (high-risk) types and account for about 70% of cervical cancers, 85% of anal cancers, 
and 47% of penile cancers (15, 16). HPV 6 and 11 are the most common non-oncogenic (low-
risk) types and account for about 90% of genital warts (15). HPV DNA is detected in 
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approximately 88- 94% of anal cancers (24, 25), 29-82% of penile carcinoma cases (19, 20), 70-
100% of penile intraepithelial neoplasia (PeIN) (18), and 80-100% of genital warts (22, 23). 
Among men, genital HPV prevalence has been reported to be as high as 73% (17).  In 2007, 
WHO (IARC) concluded that HPV 16 infection is a class 1A carcinogen for the development of 
penile, anal and oropharyngeal cancers (14).  According to 2007-2011 SEER data, incidence 
rates for oropharyngeal, anal and penile cancers were 11.0 per 100,000, 1.8 per 100,000 and 1.0 
per 100,000, respectively; with an increasing number of cases occurring due to HPV infection in 
the U.S. (18).  
          Immunization with one of the approved HPV vaccines provides an important opportunity 
for prevention of HPV infection and associated diseases in men and women.  The three currently 
available options include the bivalent (protecting against HPV 16 and 18), quadrivalent (HPV 6, 
11, 16, and 18), and recently approved 9-valent (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) 
vaccines (26, 27).  Although only one-third of girls aged 13-17 years received all three 
recommended doses of an HPV vaccine since the first HPV vaccine approval in 2006, the 
prevalence of vaccine type HPVs has decreased by 56% among females in this age group, 
highlighting the potential to eliminate the HPV types responsible for most HPV-related disease 
should  higher rates of vaccine dissemination be achieved (3).  Furthermore, a recent study 
observed a reduced prevalence of HPV 16/18 type in high grade cervical intraepithelial neoplasia 
(CIN2/3) among vaccinated women (4).   
          Vaccination leads to a robust serum antibody response that is associated with protection 
against future anogenital HPV infections and HPV-associated precancerous and cancerous 
lesions (28).  Virus-like particle (VLP)-based ELISA assays have been used to measure serum 
HPV antibodies, which correlate well with protection against incident viral infection (29). 
  
HPV 
4 
 
antibodies are also produced following natural infection but at lower levels, particularly in men 
(29-32).  While these antibodies from natural infection are likely markers of moderate immunity 
against subsequent infections and precancerous lesions among women (33- 35), the few studies 
conducted to date do not indicate a protective effect among men (30-32).  While studies have 
examined recurrence (redetection) of HPV infection among women (36-39), to our knowledge 
no previous study has examined the recurrence of HPV infections among men. Similarly only 
few studies have examined the cervical and anal genotype-concordant HPV infections among 
women (44-46).  To the best of our knowledge, studies examining sequential acquisition of 
genital and anal genotype-concordant infections, among men who have sex with women (MSW), 
have not been conducted.  
          In the current study, we plan to evaluate the baseline serum antibody status for α-mucosal 
HPV types (6, 11, 16, and 18) and their role in subsequent incidence and persistence of HPV 
infection among men.  We will also assess the concordance between genital and anal HPV 
infections for 9- vaccine type HPVs (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among MSWs.  
Findings from this study will help shed light on natural immunity against HPV in men and 
factors associated with persistence and recurrence of HPV infection.  These results will be 
helpful to promote the HPV vaccination and increase utilization among men as well as women.  
Specific aims and objectives 
          The purpose of this study is to assess the incidence, persistence, and recurrence of genital 
α-mucosal HPV infections (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) and evaluate whether HPV 
antibody status is associated with the natural history of these infections.  We plan to accomplish 
these goals by pursuing the following specific aims: 
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Aim 1: Examine the association between baseline serum α-mucosal anti-HPV antibodies 
(HPV 6, 11, 16 and 18) and subsequent incidence and persistence of incidentally acquired 
type-specific genital HPV infection among men aged 18-70 years in the HIM study cohort.  
Objective 1.1 - Determine the incidence rates of genital HPV 6, 11, 16 and 18 infections among 
baseline seronegative and seropositive subjects. 
Hypothesis 1.1 - Our hypothesis is that incidence rates do not differ by baseline HPV serostatus.  
Objective 1.2 - Determine the rate of persistence of incidentally acquired infections, with 
duration of 6 months or more, for genital HPV 6, 11, 16 and 18 infections among baseline 
seronegative and seropositive subjects. 
Hypothesis 1.2 - Our hypothesis is that rates of persistent infections do not differ by baseline 
HPV serostatus. 
Aim 2: Estimate the rate of recurrent genital α-mucosal HPV infections (HPV 6, 11, 16, 18, 
31, 33, 45, 52 and 58) among men aged 18-70 years, and the factors associated with recurrent 
infections. 
Objective 2.1 - Estimate the rate of recurrent genital HPV infections for α-mucosal HPV vaccine 
types (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among 4,123 men in the HIM study participants. 
Hypothesis 2.1 - Our hypothesis is that the recurrence rates are lower than 10% for mucosal α-
HPVs. 
Objective 2.2 – Investigate factors associated with recurrent infections among 4,123 men in the 
HIM study for genital HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
Hypothesis 2.2 - Our hypothesis is that risk of recurrent infections will be higher among men 
aged 18-30 years, those from Brazil, current smokers, men who consume alcohol more than two 
drinks per day and those with riskier sexual behaviors (≥18 lifetime sexual partners, and ≥2 
recent sexual partners).  
Aim 3: Examine sequential genital and anal genotype-concordant HPV infections (HPV 6, 11, 
16, 18, 31, 33, 45, 52 and 58) and identify factors associated with anal HPV infections 
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following a prior genotype-concordant genital HPV infection among men who have sex with 
women (MSW).  
Objective 3.1 – Identify sequential genital and anal genotype-concordant HPV infections for 
HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
Hypothesis 3.1 - Our hypothesis is that anal HPV infections are more likely to occur among 
MSW men who had a prior genotype-concordant (same genotype) genital HPV infection 
compared to men with no-prior genital infection. 
Objective 3.2 - Investigate factors associated with an incident anal HPV infection following a 
prior genotype-concordant genital HPV infection, for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 
58.  
Hypothesis 3.2 - Our hypothesis is that anal HPV infection following genital HPV infection 
occurs due to auto-inoculation and therefore is not associated with sex with female partners 
among MSW.  
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REVIEW OF LITERATURE 
 
Human papillomavirus (HPV) 
 World statistics: 
          Worldwide prevalence of HPV among women without cervical abnormalities is 11.7%, 
with the most prevalent genotypes being HPV 16 (3.2%) and HPV 18 (1.4%) (5). Higher 
prevalence has been observed in sub-Sahara Africa (24%), Eastern Europe (21%) and Latin 
America (16%).  The prevalence increases sharply among women with cervical pathology, 
reaching approximately 90% in grade 3 intraepithelial neoplasia (5). Among men, HPV 
prevalence ranging from 1.3%-72.9% has been documented in various studies (14).  
          Cervical cancer is the second most common cancer among women aged 15-44 years, with 
approximately 528,000 new cervical cancers cases and 266,000 deaths occurring annually in the 
world (47).  Almost all cervical cancers are caused by HPV infection, with HPV 16 and 18 
responsible for 70% of these cancers (11).  Apart from cervical cancers, HPV also causes anal, 
vulvar, vaginal, penile, and oropharyngeal cancers.  According to a WHO 2013 publication, 
worldwide numbers of new cases for HPV-related cancers were as follows: 27,000 anal cancers, 
27,000 vulvar cancers 13,000 vaginal cancers, and 26,000 penile cancers (21, 47).  Penile cancer 
is more common in some parts of Asia, Africa and South America, and accounts for up to 10% 
of cancer cases among men (47).  Worldwide annual age-adjusted incidence and mortality rates 
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for oropharyngeal cancer (OPC) are 5.9 and 3.3 per 100,000 persons, respectively (47).  In 
developed countries, HPV associated OPC incidence rates are increasing among men and HPV 
16 type has been implicated in most cases (48, 49).   
U.S. statistics: 
          Each year 26,000 new cancer cases (17,000 in women and 9,000 in men) are attributable to 
HPV in the U.S. (50).  Cervical cancer is the fourth most common cancer among women aged 
15-44 years in the U.S., and about 3.9% women in the general population have HPV 16/18 
infection at any given time (51).  Annual incidence and mortality rates for cervical cancer are 7.8 
and 2.3 per 100,000 women based on SEER 2007-2011 data (15),  resulting in approximately 
13,000 new cervical cancer cases and 6,600 cervical cancer deaths each year (51).  For vulvar 
cancers, incidence and mortality rates are 2.4 and 0.5 per 100,000 women, respectively (15).  
Anal cancers are also associated with HPV infection with annual incidence and mortality rates of 
1.8 and 0.2 per 100,000 in men and women (15). Penile cancers are rare in the U.S. and they 
account for less than 1% of cancers diagnosed among men (15). Oropharyngeal cancer (OPC) 
annual incidence in the U.S. is 10.6 cases per 100,000 persons, with an annual mortality rate of 
2.5 per 100,000 persons (15). OPC incidence rates are about 4 times higher in men compared to 
women (52).  Approximately 45,780 new cases and 8,650 deaths were attributed to OPC in the 
US in 2014 (53).   
HPV classification  
          HPV is a non-enveloped double-stranded DNA virus that primarily infects stratified 
epithelia (54).  HPV infections can be classified as mucosal (genus) and cutaneous, which 
include α, β, γ, μ (Mupa), and Nv (Nupa) genera (55).  These genera differ according to the 
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primary site of infection (Table 1) (56-58).  The α-HPV genus includes the most important HPV 
types associated with cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers and 
genital warts; including HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 (56).  Alpha HPV genotypes 
can be further classified as high-risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 68, 69, and 
82) or low-risk (HPV 6, 11, 40, 42, 43, 44, 54, 61, 72, and 81), based on their oncogenicity
 
(57).  
Most HPV infections (about 90%) are asymptomatic and resolve within two years, but persistent 
HPV infections can cause a variety of cancers and benign diseases (59).   
Table 1: Different genera of papillomavirus family with HPV types and type of tissues 
affected (58)
 
Genus HPV type Tissue 
tropism 
Alpha 
papillomavirus 
6, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 
44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 
66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 83, 84, 85, 
86, 87, 89, and 90  
 
7, 40, 43 and c91 
 
2, 3, 10, 27, 38, 29, 57, 77, 78 and 94 
Mucosal 
 
 
 
 
 
Mucosal and 
cutaneous 
 
Cutaneous 
Beta 
papillomavirus 
5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 
36, 37, 38, 47, 49, 75, 76, 80, 92, 93 and 96 
Cutaneous 
Gamma 
papillomavirus 
4, 48, 50, 60, 65, 88 and 95 Cutaneous 
Muppa 
papillomavirus 
1 and 63 Cutaneous 
Nupa 
papillomavirus 
41 Cutaneous 
 
Source: Reproduced from the publication by Koning et al (2008)
58
. 
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Mechanism of infection  
          HPVs infect keratinocytes in the basal cell layer of the stratified epithelium, which is the 
only tissue in which they can replicate (60).  HPVs replicate in the nucleus of keratinocytes in a 
differentiation-dependent manner, meaning that viral gene replication and transcription are 
tightly controlled by keratinocyte differentiation (60).  Expression of HPV viral genes leads to 
expression of six nonstructural viral regulatory proteins (E1, E2, E4, E5, E6 and E7) and two 
structural viral capsid proteins (L1 and L2) (61).   The E6 and E7 viral proteins are oncogenes, 
leading to deactivation of p53 and pRb tumor suppressor proteins (61).  Various HPV protein 
encoding genes and organization of the HPV genome are shown in Figure 1 (62).    
 
Figure 1: Genomic organization of high-risk mucosal HPV virus (62) 
Source: Used with permission of Dr. Anna Giuliano, from the HIM Study presentation materials.  
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          As shown in the figure, the HPV viral genome contains early (E) regions and late (L) 
regions, which indicate the position of the gene and their timing of expression in the viral life 
cycle (61, 62).  E1 and E2 proteins help with viral replication and transcription, while E4 helps 
with viral release. E6 and E7 are major transforming proteins of the oncogenic HPVs and also 
have roles in the normal viral cell cycle (62).  E5 protein has a role in growth stimulation and 
immune evasion (61, 62).  Among the late region proteins, L1 is a major capsid protein and L2 is 
a minor capsid protein.  The L1 major capsid protein binds with the basement membrane heparan 
sulfate proteoglycans (HSPGs), which are exposed due to any previous trauma to the skin (60).  
Gene replication and transcription are controlled by the upstream regulatory region (URR), 
which also contains promoter and enhancer regions (60-62). 
          The cell-mediated immune (CMI) response is responsible for clearing HPV-associated 
infection and benign lesions and is accompanied by a CD4+ T cell-dominated response (62).  
Failure of an effective CMI response, followed by high-risk HPV infection, can lead to persistent 
infection and increased probability of high grade intraepithelial neoplasia and invasive 
carcinoma (62).  HPV infection effectively evades innate immune recognition, due to the fact 
that HPV is exclusively an intra-cellular infection; there is an absence of viremia, virus-induced 
cell death, and replication-associated inflammation (62).  HPV also downregulates innate 
immune signals; which leads to inhibition of type I interferons (IFN-α and IFN-β), lack of 
signals for Langerhans cell activation/migration, and lack of recruitment of stromal dendritic and 
macrophage cells
 
(62).  Evasion of these immune responses allows infections to persist for 
months to several years and it may lead to high-grade intraepithelial neoplasia and upregulation 
of E6 and E7 proteins, which further suppresses the immune response (62).  After HPV infection, 
non-dividing epithelial cells retain a normal active cell cycle, which may result in thickened, 
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exophytic lesions (60).  Virus is released as the epithelial cells exfoliate. In cells that do not 
senesce, the viral genome integrates into the host chromosome which is associated with 
neoplastic progression (60).   
          As indicated previously, HPV infection and lesions are primarily targeted by CMI (60-62), 
with antibody response (humoral response) shown to follow the CMI response (62).  Unlike the 
antibody response following infection with other viruses, lower antibody levels are detected in 
both animals and humans, which may be due to HPV’s ability to evade the innate immune 
recognition (61, 62).  As viral particles are released at the surface of the epithelium (rather than 
in blood or lymph nodes) as cell exfoliates and there is no viremia, circulating immune cells are 
not exposed to HPV. The humoral response is initiated in lymph nodes and this may be one of 
the explanations for lower antibody levels (62). Furthermore, current methods for serum 
antibody measurement may not be sensitive enough to detect low antibody levels and this may 
explain different findings observed in previous studies (31, 62).  
HPV vaccines  
          Three HPV vaccines are currently approved for use in the U.S. A quadrivalent vaccine 
(Gardasil, HPV 6, 11, 16, 18) approved in 2006 (63,64), a bivalent vaccine (Cervarix; HPV 6 and 
11) approved in 2009 (65), and a nonavalent vaccine (Gardasil 9, HPV 6, 11, 16, 18, 31, 33, 45, 
52, 58) approved in 2014 (66).  Among the types covered by these vaccines, HPV 16 and 18 are 
responsible for about 64% of invasive cancers, 70% of cervical cancers; while HPV 6 and 11 
cause 90% of genital warts and most cases of recurrent respiratory pappilomatosis (63, 66).  
These vaccines include virus-like particles (VLPs), which are prepared from the recombinant L1 
capsid protein of HPV, and are therefore not live vaccines (63).  HPV vaccine is recommended 
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starting at age 11-12 years for routine vaccination (67).  The Advisory Committee on 
Immunization Practices (ACIP) of the CDC also recommends vaccination for 13-26 year old 
females and 13-21 year old males not vaccinated previously (66).  These recommendations are 
extended to include men up to 26 years of age who are considered to be at higher risk of HPV 
acquisition (men who have sex with men or who are immune-compromised) (66).  
          In December 2014 a 9-valent vaccine (Gardasil-9) covering 5 additional HPV types (31, 
33, 45, 52 and 58), along with quadrivalent HPV types (HPV 6, 11, 16 and 18) was approved in 
US (66).  The 5 additional HPV strains are responsible for about 10% of HPV associated cancers 
and about 15% of cervical cancers (66).  In a phase III clinical trial, the 9-valent vaccine 
demonstrated 96.7% efficacy in the prevention of cervical intraepithelial neoplasia grade 2, 
vulvar intraepithelial neoplasia grade 2 or 3, and vaginal intraepithelial neoplasia grade 2 or 3 
caused by HPV 31, 33, 45, 52, or 58 (66). 
          According to a 2014 report, vaccine coverage for HPV among adolescent girls in the U.S. 
was 57.3% for one or more doses and 37.6% for all three doses (68).  Coverage among 
adolescent boys was much lower, with 34.6% coverage for one or more doses and 13.9% for all 
three doses (68).  HPV vaccination coverage among adolescents has not increased in recent 
years, and the coverage rates are far below the Healthy People 2020 target of 80% coverage for 
both adolescent girls and boys (68).
 
Australia was the first country to launch a government-
sponsored HPV vaccination program, and between 2007-2009, approximately 83% girls aged 
12-17 years received at least one dose of the quadrivalent HPV vaccine, and 70% completed all 
three-dose series (69).  Four years after initiation of  this vaccination program, there was a 
significant reduction in the prevalence of vaccine-type HPVs (6, 11, 16, and 18) (69).
 
 
Reductions in HPV-associated diseases and pre-malignant lesions in vaccinated populations have 
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also been documented in Australia, Denmark, and the U.K. (70-72). Thus, increased efforts to 
expand HPV vaccination coverage are required to prevent HPV- associated diseases in the U.S. 
HPV infection among men  
          Although HPV natural history studies originally focused exclusively on women, the 
importance of HPV etiology and diseases among men has increasingly been recognized and 
studied.  One such study, the HPV Infection in Men (HIM) Study is a prospective natural history 
study conducted among healthy men from three different countries (U.S., Brazil, and Mexico)
 
(2). The HIM Study was the first large study to report the prevalence and type distribution of 
HPV among men residing in the USA, Brazil and Mexico (2).  The initial findings of the HIM 
Study reported an overall HPV prevalence of 65.2%, with the highest prevalence in Brazil 
(72.3%), followed by Mexico (61.9%) and the U.S. (61.3%) (2).  A systematic review in 2006 
detected HPV prevalence ranging from 1.3%-72.9% among men, with more than 56% studies 
reporting prevalence over 20 % (14) with HPV 16 being the most commonly detected type.  Five 
cross-sectional studies described young age at first sexual intercourse, greater number of lifetime 
and recent sexual partners, and high frequency of intercourse as risk factors for HPV infection in 
men (73-76).  The HIM study reported an incidence rate of 38.4 per 1,000 person month (95% CI 
34.3-43.0) for new genital HPV infections (8).  For oncogenic HPV infections, this study 
reported hazards ratio (HR) of 2.40 (95% CI 1.38-4.18) for at least 50 partners vs. not more than 
one partner and HR of 2.57 (95% CI 1.46-4.49) for at least three male partners vs. no recent 
partners (8).  Average duration of an HPV infection was 7.5 months and for HPV 16 was 12.2 
months (8).  Earlier cross-sectional and longitudinal studies also indicated that circumcision and 
condom use
 
were associated with reduced risk of HPV infection among men (14, 73-78).  The 
HIM study also showed that men have a consistent risk of HPV across the lifespan (ages 18-70 
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years)
 
(13, 81).  Oncogenic HPV detection was independently associated with lifetime and recent 
number of sexual partners, while non-oncogenic HPV infection was associated with only lifetime 
number of sexual partners (82).  A few studies have found that smoking is a possible risk factor, 
while others found no association (83-85).   
Previous literature 
HPV antibodies and incident infection  
Among women 
          Various studies among women have assessed the effect of anti-HPV antibodies on 
subsequent risk of incident infection acquisition.  High levels of HPV 16 IgG antibodies were 
shown to be associated with reduced incidence of subsequent infection with HPV16  and related 
types (31, 33, 35, 52, and 58) (86).  Persistent antibodies to HPV 16 (p =0.02), HPV31 
(p<0.001), HPV33 (p=0.03), HPV35 (p=0.002), HPV52 (p=0.007), HPV45 (p=0.003), and 
HPV53 (p=0.01) were also found to be associated with reduced risk of HPV incidence (87).  
Further studies also have shown protection against HPV infection among seropositive 
individuals (33-35, 88, 89).  Although three studies did not find any association between anti-
HPV antibodies and subsequent protection against incident type-specific HPV infection (90-92), 
the majority of studies indicated a moderate protective effect of anti-HPV antibodies against 
subsequent infections among women. Various studies have indicated a higher seroprevalence of 
anti-HPV antibodies among women compared with men for both oncogenic and non-oncogenic 
HPV types (93-97). Factors including differential immune response, serum antibody cut-off 
levels, differences in assay techniques, and different durations of antibody levels have been 
suggested for the difference in antibody response observed among women in these studies.  
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Among men 
          Only three studies have previously assessed the association between HPV antibodies and 
subsequent incident infection in men (29-31).  A study conducted in HPV Infection in Men study 
cohort Tucson-Arizona, did not show a protective effect for HPV 16 and 18 antibodies (29),
 
but 
this study had limited follow-up time, sample size, and availability of quantitative assessments 
for serum antibody levels.  A study based on 2,187 HIM Study participants (from USA, Brazil 
and Mexico) also did not show an association between serum antibodies and reduction in 
subsequent infection for HPV 16 (30), although this study did not include all HIM Study 
participants or data for HPV genotypes 6, 11, and 18.  A recent study among HIV-negative and 
HIV-positive men did not show protective effects against subsequent infection but the study only 
included MSM (men who have sex with men) subjects (31). Thus, previous studies do not 
provide sufficient evidence regarding the association between anti-HPV antibodies and 
subsequent HPV infection among all men. 
          Differences between men and women’s antibody response to HPV infection may be due to 
differential sex-related immune responses, differences in assay techniques, and varying duration 
of serum antibody presence (30). Various studies have reported sex differences for HPV 
seroprevalence, with women having higher seroprevalance compared to men (93-98).  HPV 
infection of keratinized epithelium among men may be less likely to induce an immune response, 
and as a result lower levels of antibodies, compared to larger mucosal surface area among 
women (30).  Difference in assay techniques can also be a possible explanation. For example, 
VLP-based direct-binding ELISA assay that measures total type-specific binding IgG antibodies 
may yield different results compared competitive neutralization assay that binds only 
neutralizing epitopes in HPV viral capsid (28, 30).  Assessment techniques and cut-off levels of 
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serum antibodies can also affect the observed association.  For example, use of only high 
antibodies for 2 or more visits may yield different results compared to assessment of serostatus 
only at baseline (86, 91, 92).   
Recurrent HPV infections  
Among women 
          Few studies have examined recurrent infection or redetection of HPV infection after 
clearance among women.  Reinfection was associated with new sexual partners, including among 
older women (38).  Winer et al. reported that redetection of 19.4% incident infections occurred 
within a year (36).  A study by Rodriguez et al. assessed type-specific recurrence of carcinogenic 
HPV types and development of subsequent cervical intraepithelial neoplasia (99).  They found 
that 7.7% of HPV-infected women had intervening negative results, while 2.7% had definite 
clearance (≥ 2 intervening negative results) followed by re-appearance (99).  Moscicki et al. 
reported that 18.1% of HPV 16 infections were redetected among women who cleared an HPV 
16 infection, and factors associated with risk for redetection included douching, current use of 
medroxyprogesterone, reporting more than one sex partner or having a new sex partner, and 
having a sexually transmitted infection (100).  
          To our knowledge, no previous study has examined the recurrence (redetection) of HPV 
infection after clearance of initial incident infection among men.  
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Concordant genital and anal HPV infections  
Among women 
          Only a few studies have assessed concurrent genital-anal infection or sequential HPV 
infection starting with a genital infection followed by an anal HPV infection with the same 
genotype among women.  Hernandez et al. assessed 1,363 women with paired anal and genital 
samples in a cohort of adult women in Hawaii (44).  According to their results, risk of concurrent 
anal infection was 3-fold higher among women with cervical HPV infection as compared with 
women of the same age and from the same population without cervical HPV infection.  They 
also reported a higher (26% identical and 53% partly identical) genotype-specific concordance 
among concurrent anal and cervical infection, possibly due to a common source of infection (44).  
Goodman et al. examined the genotype-concordant cervical HPV infection and subsequent anal 
HPV infection among 751 women in this Hawaii HPV cohort (45).  They reported a Relative 
Risk (RR) of 20.5 (95% CI, 16.3-25.7) for acquiring a secondary anal infection after a primary 
cervical infection with the same HPV genotype (45).  Goodman et al. also showed similar results 
with Hazards Ratios (HR) of 17.33 (95% CI 10.22-29.39) for any HPV type, HR of 17.95 (95% 
CI, 9.34–34.52) for high risk HPV and HR of 16.24 (95% CI, 6.57–40.16) for low risk HPV 
types (46).  A cross-sectional study of 211 adult women in American Samoa by Hernandez et al, 
2012 reported that 4% of women had concurrent cervical and anal HPV (101).  They also found 
that having a cervical HPV infection was associated with anal HPV with an age-adjusted OR 
3.32, 95% CI (1.10-10.00)
 
(101).  Guler et al, 2013 evaluated the prevalence of coexisting anal 
HPV infection and concordance of HPV types in women with cervical HPV infection (102).  
They reported a high prevalence (52%) of coexisting cervical and anal infections, with 20% total 
concordance and 58% partial concordance between the two sites (102).  
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          To the best of our knowledge, similar associations for genotype-concordant genital and 
anal infection have not been examined among men.  Our study will utilize the data from 
participants of the HIM study cohort, who agreed to provide anal samples for the study (2,103, 
104).  Factors associated with incidence and persistence of anal HPV infection in this cohort has 
been described previously (103, 104).  Briefly, HPV anal HPV prevalence was 12.2% among 
MSW and 47.2 % among MSM subjects (103).  More than 10 lifetime female sex partners and a 
primary sexual relationship of <1 year in duration were independently associated with anal HPV 
detection among MSW subjects (103).  Young age, more than two male anal sex partners in the 
past three months, and never using a condom for anal sex in the past six months were associated 
with detection of any anal HPV among MSM subjects (103).  The incidence rate of anal HPV 16 
and 18 among MSW subjects were 0.7 and 0.9 per 1000 person-months, respectively (104).  
Among MSM subjects, incidence rates for HPV 16 and 18 were 4.8 and 3.8 per 1000 person-
months, respectively (104).  Among MSM 5.1% subjects had a persistent HPV 16 infection, 
while 0.6% MSW subjects had persistent infection for any genotype (104).  Cigarette smoking 
was associated with persistent infection of any genotype among both MSM and MSW subjects 
(104).  We will use data for MSW subjects for the analysis and examine the genotype-concordant 
genital and anal infection among men.  
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Introduction:  
          Genital HPV prevalence among men exceeds 70% in some regions of the world (105), 
with HPV DNA detected in 29-82% of penile cancers (106, 107) and 80-100% of genital warts 
(108, 109). Furthermore, nearly 10,000 new cases of HPV-related oropharyngeal cancers among 
men are diagnosed in the U.S. each year (110). Although the antibodies produced following HPV 
vaccination among men provides protection against future ano-genital HPV infections and 
related diseases (111), it is unclear whether the antibodies produced after natural HPV infection 
are sufficient to protect against subsequent infection in men.  
          Among women, antibodies produced in response to natural HPV infection are markers of 
past infections and have been shown to provide partial immunity against subsequent infections 
and precancerous lesions (112-114); however, not all studies observed these protective effects 
(115-117). Differences in study findings may be due to the use of different antibody assays, 
serum antibody levels, and time since first exposure to HPV (118).  A prospective study of HPV 
infection among men in Arizona did not show protective effects of circulating HPV antibodies 
(119). However, this study was limited by a short follow-up time, small sample size, and lack of 
a quantitative serum antibody assessment. An initial study of 2,187 participants in the 
multinational HPV Infection in Men (HIM) Study also did not show an association between 
serum antibodies and reduction in subsequent HPV 16 infections (118). However, this study was 
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limited to only one HPV type with a median duration of two years follow-up. A recent study 
among HIV-negative and HIV-positive men also did not show protective effects against 
subsequent HPV infection for multiple HPV types, but the study was restricted to men who have 
sex with men (MSM) (120).  
          In the current study, we provide the first comprehensive evaluation of incident genital 
HPV 6, 11, 16, 18 (any duration infection and six-month persistent infections) by baseline 
antibody status among the entire HIM Study cohort (n=4,123) followed for a median of 4.1 
years.  
Methods: 
Study population 
          The HIM Study is an ongoing multinational study of the natural history of HPV among 
men in Tampa, Florida (U.S.), São Paulo (Brazil), and Cuernavaca (Mexico). Details of this 
study have been described previously (121). Briefly, healthy men were enrolled at each study site 
and followed for a median follow-up of 4.1 years, with an average interval of 6.9 months 
between visits. Men were eligible for the study if they: a) were 18–70 years of age; b) were 
residents of one of the study sites; c) had no previous diagnosis of penile or anal cancers; d) had 
never been diagnosed with genital or anal warts; e) had no symptoms of a sexually transmitted 
infection (STI) and were not receiving treatment for an STI; f) were not participating in an HPV 
vaccine study; g) had no history of HIV or AIDS; h) had no history of imprisonment, 
homelessness, or drug treatment during the past six months; and i) were willing to comply with 
10 scheduled visits every six months for four years with no plans to relocate during that time. 
Subjects who reported never being sexually active and subjects who received HPV vaccines 
were excluded. 
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          To increase access to men across a broad range of ages, sexual behaviors, and HPV risk, 
participants were recruited from the general population, universities, and organized healthcare 
systems. In Brazil, men were recruited from a facility for urogenital care (Centro de Referencia e 
Tratamento de Doencas Sexualmente Transmissiveis e AIDS) and through general media 
advertising. Men with non-sexually transmitted infections and related conditions (e.g. kidney 
stones, hydronephorsis, and hypertrophied bladder) were included in the study. Furthermore, 
partners and spouses of participants in a large cohort study of the natural history of HPV and 
cervical neoplasia in women conducted in São Paulo were recruited for the HIM Study. 
Employees and beneficiaries of the Instituto Mexicano de Seguro Social, factory employees, and 
permanently assigned officials of the Mexican army were recruited at the Cuernavaca, Mexico 
site. In the U.S., men were recruited from the University of South Florida and the greater Tampa 
Bay area. Flyers were distributed, and monthly educational presentations were carried out to 
promote the study and increase recruitment. Furthermore, mailed brochures and flyers and 
advertisements in local and university papers were used to recruit subjects. 
          All eligible participants signed an informed consent, and approval was obtained from the 
human subjects committees of the University of South Florida (Tampa, FL), Ludwig Institute for 
Cancer Research (São Paulo, Brazil), Centro de Referencia e Treinamento em Doencas 
Sexualmente Transmissíveis e AIDS (São Paulo, Brazil), and Instituto Nacional de Salud Publica 
de Mexico (Cuernavaca, Mexico). A total of 4,123 HIM Study participants were eligible for this 
study.  
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Computer assisted self-interviewing (CASI) 
          Each participant completed an extensive self-administered demographic and behavioral 
questionnaire assessing country of residence, age, race, ethnicity, marital status, education, 
smoking status, alcohol consumption, and a detailed sexual behavior history. The questionnaire 
was completed at baseline and at each six month follow-up visit. The questionnaire required 
approximately 20 minutes to complete and was administered using computer-assisted self-
interviewing (CASI). The CASI method has been shown to be superior in reliability and 
consistency compared to the paper-based questionnaire method (p <0.05) and is reported to be 
user friendly, even for computer-inexperienced subjects (122). Furthermore, the CASI method 
reduces errors due to faulty execution of skip instructions or confusing skip patterns and 
encourages more complete reporting of sensitive behaviors, such as sexual behavior history (122, 
123). Other advantages of CASI include low cost, (as interviewers are not required, and there is 
no need to enter data into the computer separately), lower refusal rates for sensitive topics, and 
ease of use in multisite trials (122, 124, 125). 
Baseline serum antibody testing 
          A 10 milliliter venous blood sample was collected at baseline to measure serum antibodies 
against four HPV genotypes (HPV 6, 11, 16, and 18). Serum anti-HPV antibody assessments for 
HPV genotypes (6, 11, 16, and 18) were carried out using a virus-like particle (VLP)-based 
enzyme-linked immunosorbent assay (ELISA) (126). Details of this assay have been described 
previously (127). Briefly, insect cells from recombinant baculoviruses expressing HPV L1 
capsid proteins were used to produce HPV VLPs. Absorbance values in optical density (OD) 
were measured to assess seroreactivity. Serum samples from children (1-10 years old) were used 
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as a negative control. The cut-off point for seropositivity for each HPV genotype was selected as 
five SD above the mean absorbance value among the children. Positive and negative laboratory 
serum controls were used in each assay run for quality control purposes. Laboratory staff was 
blinded to participants’ HPV DNA status. 
External genital HPV DNA samples 
          Three prewetted Dacron swabs were used to collect genital cell specimens from the 
coronal sulcus/glans penis, penile shaft, and scrotum and were later combined to form a single 
sample (121, 128). All specimens were stored at -80°C until genotyping was conducted. The 
QIAamp DNA Blood Mini Kit (QIAGEN) was used to extract DNA from genital cell specimens. 
Roche Linear Array kits were used for PCR and HPV DNA genotyping to detect 37 different 
types of HPV (129). The presence of human β-globin was used to assess specimen adequacy 
with an overall β-globin positivity of >98%.  
Statistical analysis 
          Demographic characteristics were compared between seronegative and seropositive men at 
baseline using Chi-square tests with Monte Carlo estimation of exact p-values. Only men who 
were DNA-negative for the respective HPV type at the baseline visit were included in analyses. 
Separate analyses were carried out for each of the four HPV genotypes (HPV 6, 11, 16 and 18) 
by duration of infection (any duration for incident infections and >6 months duration for 
persistent infection).  
          Incidence proportions (all incident HPV 6, 11, 16, and 18 infections regardless of duration) 
and six-month persistent incidence proportions were calculated at each six-month interval among 
subjects who had one or more follow-up visits after baseline. Follow-up times were calculated 
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based on visit dates and participants who were late for their visit were included in the appropriate 
time interval for the analysis. To estimate incidence proportions, the first detection of HPV DNA 
at a follow-up visit was defined as an incident HPV infection (numerator). The number of 
subjects who tested negative for HPV DNA at the beginning of each study interval was defined 
as the at-risk population (denominator). For six-month persistent infections, a persistent infection 
was defined as HPV DNA detection at two or more consecutive visits. Persistent infections also 
included subjects with an intervening negative result (n= 20 for HPV 6, n=5 for HPV 11, n=22 
for HPV 16 and n= 11 for HPV 18). Participants who were DNA- negative for the given HPV 
type (at risk of acquiring a new infection) at the beginning of each study interval were defined as 
at-risk subjects for six-month persistent infection.  
          Kaplan-Meier (KM) curves were constructed for incident and six-month persistent 
infections for each of the four HPV genotypes (6, 11, 16 and 18). Cumulative incidence for each 
genotype was compared between seropositive and seronegative subjects, with the log-rank test 
used to determine significant differences by serum antibody status. Cox proportional hazard 
models were used to calculate crude and adjusted hazard ratios (aHR) and 95% confidence 
intervals (CI). A list of candidate variables was created based on descriptive analyses, previous 
literature, and assessment of confounding by each variable. Variables were evaluated in both 
backward and forward stepwise models. Final models included variables based on best-fit 
approach based on the lowest Akaike information criterion (AIC) values. As sexual behavior 
prior to acquisition of incident infections strongly influences HPV acquisition, we included the 
following sexual behavior variables as time-varying covariates in final adjusted Cox models: 
lifetime number of female sexual partners, number of new female sexual partners in the past 6-12 
months, frequency of sexual intercourse with female partners in the past 6-12 months, lifetime 
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number of male sexual partners, and number of new male sexual partners in the past 6-12 
months. Due to the differences in HPV seroprevalence by sexual orientation, stratified analyses 
were also conducted. To evaluate whether antibody levels were associated with subsequent 
detection of incident infections, we categorized serum antibody levels into the highest tertile and 
lowest two tertiles and compared these two groups to seronegative men (113, 120). 
Results:  
          Serum antibody and HPV genotyping data were available for 4,103 subjects at baseline. 
We excluded 250 (HPV 6), 55 (HPV 11), 311(HPV 16) and 90 (HPV 18) subjects who were 
DNA-positive at the baseline visit for the respective HPV type. Therefore, baseline 
seroprevalence analyses included 3,851 (HPV 6), 4,046 (HPV 11), 3,790 (HPV 16), and 4,011 
(HPV 18) subjects who were DNA-negative for the specific HPV genotype.  
          Overall, baseline HPV6, 11, 16, and 18 seroprevalence was 8.1%, 13.9%, 12.4%, and 
10.8%, respectively. Significant differences were observed between seropositive and 
seronegative men for various covariates (Table 2.1). Seroprevalence increased with increasing 
age, with the highest seroprevalence for HPV 6 (9.4%), 11 (16.2%), and 16 (16.4%) observed 
among men ages 31-44, and the highest HPV 18 seroprevalence (17.9%) among men ages 45-73. 
Brazil had the highest seroprevalence for HPV 6 (10.8%), 16 (16.9%), and 18 (13.0%), while 
Mexico had the highest seroprevalence for HPV 11 (18.8%). Men who have sex with men 
(MSM) had the highest seroprevalence for all four genotypes (HPV 6: 23.2%, HPV 11: 27.6%, 
HPV 16: 28.6%, and HPV 18: 29.3%). Seroprevalence was highest among men reporting ≥10 
lifetime male sexual partners (30.0%, 37.8%, 39.0%, and 40.4% for HPV 6, 11, 16, and 18 
respectively).   
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          For HPV 6, 11, 16, and 18, the total numbers of incident infections were 319 (10.3%), 111 
(3.5%), 362 (12.4%), and 200 (6.2%) among seronegative men, and 30 (10.6%), 17 (3.3%), 70 
(16.7%), and 22 (5.6%) among seropositive individuals, respectively. Cumulative incidence 
among seropositive individuals was higher after 18 months for HPV 16 (p-value= 0.007, Figure 
2.1a, table 2.2a). For HPV 11 and 18, incidence proportions were generally lower among 
seropositive individuals until the 13-18 month interval, followed by similar proportions (HPV 11 
and 18) after 24 months. KM curves indicated a similar pattern with overall non-significant p-
values (p = 0.76 for HPV 11 and p = 0.69 for HPV 18) for the association between serostatus and 
HPV acquisition. For HPV 6, cumulative incidences among seropositive and seronegative 
subjects was similar (p-value= 0.728).  
          The total numbers of incident six-month persistent infections were 100 (3.5%), 37 (1.3%), 
120 (4.5%), and 74 (2.5%) among seronegative men and 7 (2.8%), 2 (0.4%), 21 (5.5%), and 2 
(0.6%) among seropositive individuals for HPV 6, 11, 16 and 18, respectively. Six month 
persistent HPV 16 infections did not differ significantly between seronegative and seropositive 
individuals (Figure 2.1b, Table 2.2b). The overall number of six-month persistent HPV 11 and 
18 infections observed was low (two infections for each type over 4.1 year follow-up period). 
Six-month persistent infections were not observed prior to month 31 among HPV 11seropositive 
individuals and prior to month 19 for HPV18 seropositive individuals. Significantly lower 
incidence of six-month persistent HPV 18 infections was observed among seropositive 
individuals (p=0.02).  
          Risk of an incident HPV 16 infection was significantly higher among seropositive 
compared to seronegative men (aHR 1.37, 95% CI 1.01, 1.86) (Table 2.3). A similar non-
significant pattern was observed for risk of six-month persistent HPV 16 infections (aHR 1.26, 
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95% CI 0.79, 2.01). Serostatus was not associated with risk of HPV 6, 11, and 18 incident 
infections. However, risk of persistent HPV 18 infection was significantly lower among 
seropositive men in unadjusted analyses (crude HR 0.22, 95% CI 0.06-0.91), but failed to reach 
significance in the adjusted model (aHR 0.19, 95% CI 0.03, 1.37). In separate analyses adjusting 
for demographic and sexual behavior variables one at a time, similar results to those shown in 
Table 3.3 were observed (Appendix Table 2.1).  
           Table 3.4 shows the risk of incident and six-month persistent HPV 16 and 18 infections 
by serostatus and sexual orientation. No significant associations were observed likely due to the 
relatively small sample sizes in each stratum. No evidence of effect modification was observed 
for HPV 18. However, serostatus was non-significantly associated with a decreased risk among 
MSM and increased risk among heterosexual men. Similarly, no significant associations were 
observed for HPV 6 and 11 (Appendix Table 2.2). In analyses by serum antibody levels, high 
levels (highest tertile) of antibody were not significantly associated with reduced risk of 
subsequent genital HPV infection (Appendix Table 2.3). In analyses comparing the lower two 
tertile groups to the seronegative group, the incidence rate ratio for HPV 16 was 1.40 (945% CI, 
1.01-1.89) and for persistent HPV 18 was 0.16 (95% CI 0.004-0.93).These results are 
comparable to the results discussed previously.   
          To address the issue of small sample size and to increase power, we conducted analyses by 
combining seropositive individuals for any of the four HPV types and compared them to 
seronegative individuals for all four HPV types. These analyses did not indicate significantly 
higher HR for subsequent HPV 16 incident infection, but for persistent HPV 18 infection a 
significant protective effect was observed in adjusted models (aHR 0.42, 95% CI 0.19, 0.93) 
(Table 2.5).  
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Discussion:  
          In this study of men, baseline seropositive status was not associated with a reduction in 
subsequent incident or six-month persistent HPV 6, 11, and 16 infections. In fact, HPV 16 
seropositive men had a higher HPV 16 incident infection rate compared to HPV 16 seronegative 
men. A possible protective effect was observed for HPV 18 persistent infections among 
seropositive individuals, but the small number of infections requires a cautious interpretation of 
these results. In general, natural immunity after HPV infection was not associated with a reduced 
risk for subsequent HPV infections among men. 
          This is the first study to report a significantly higher risk of incident genital HPV 16 
infections among seropositive men. In the few studies that have assessed the association of 
antibodies generated following natural HPV infection and protection against subsequent genital 
HPV infections in men, results have either been inconclusive or have not shown an association 
(118, 119, 112). The current study is an extended analysis of previous work from our group 
(118), in which we showed a non-significant increased risk for incident (aHR 1.22, 95% CI 0.83, 
1.79) and persistent HPV 16 genital infections (aHR 1.05, 95% CI 0.51, 2.16).  
          The higher HPV 16 incidence among seropositive men was not observed consistently over 
the entire follow-up period. Similar or lower genital HPV 16 incidence was observed among 
seropositive and seronegative men up to the month 18 follow-up visit. Similar initial protective 
effects against HPV 16 and other HPV genotypes have been documented among women, 
followed by gradual waning of naturally induced IgG antibody levels over time (130-136). High-
risk sexual behavior among seropositive men, compared to seronegative men, may have led to 
higher rates of incident infections among them. However, if this was the case, higher incidence 
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among seropositive men should have been observed for other HPV types as well, and not just for 
HPV 16. Although we adjusted for sexual behavior variables as time-varying covariates, there is 
still a possibility that residual confounding occurred. There is also a possibility of not capturing 
precise sexual behavior related risk due to error in reporting sexual behavior in the self-reported 
questionnaire. Higher risk of incident and persistent infections among HPV 16 seropositive 
individuals may also indicate possible reactivation of prior latent infection (137).  
          In this study, incident and persistent HPV 11 and 18 infections were generally lower 
among seropositive subjects. Lower incidence (especially for persistent HPV 18) may be 
suggestive of a transient protective effect, which gradually wanes after 18 months, as the KM 
analyses indicated. However, due to the small number of HPV 18 events, this association failed 
to reach statistical significance. Additional studies are needed to understand the role of anti-HPV 
18 antibodies among men.  
          Factors including differential immune response by gender, differences in assay techniques, 
and different durations of antibody levels have been suggested as possible explanations for the 
difference in antibody response observed among men and women (118, 131, 138, 139). 
Numerous studies have indicated a higher seroprevalence of both oncogenic and non-oncogenic 
HPV types among women compared with men (140-146). A lower level of antibody response 
following infection of keratinized epithelium among heterosexual men compared to mucosal 
epithelial infection in heterosexual women may be a possible explanation for this gender 
difference (118). Inclusion of non-neutralizing antibodies in our study may have led to 
overestimation of overall serum antibody levels and may have biased the results toward the null. 
Serum antibody cut-off levels may also affect the observed association. We therefore carried out 
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analyses using the highest versus the lowest two tertiles of serum antibodies, and the results were 
not substantially different.  
          To the best of our knowledge, our study is the first to assess the effect of serum antibody 
status for all four major vaccine type HPVs in a large, multicenter cohort of men with a long-
term follow-up. Despite these strengths, some limitations may have influenced the results. Serum 
antibody levels were determined at a single baseline visit in our study. Men with prior exposure 
may have been misclassified as seronegative due to lower seroconversion rates, waning antibody 
response, and time-lag between exposure and antibody response. This misclassification is likely 
to be non-differential and may have attenuated findings toward the null. Misclassification of 
HPV infection is also a possibility, although we utilized robust methods for DNA detection that 
are well-established (121). Furthermore, single baseline visit DNA negative subjects were 
assumed to be the at risk population and were considered eligible for the study. We ran a 
separate analysis using more stringent criteria of requiring two negative visits (baseline and first 
six months visit) to qualify for entry into the analyses. Use of this stringent criterion also did not 
alter study results.    
          We did not have information about infections that may have occurred prior to the study 
start. These infections may not have cleared but instead remained latent at low copy numbers 
(137). Latency for HPV infection has been described in animal models and recently, reactivation 
of latent infection has been demonstrated among immuno-compromised individuals (137). 
Assessment of previous infections is challenging, especially among men who have been sexually 
active for a long period of time. Furthermore, current HPV DNA detection methods may not be 
sensitive enough to detect low viral load of latent infection or reactivations that last for a short 
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time period (118). Future studies are needed to explore the effect of latent HPV infections and 
their reactivation among healthy individuals. 
          In conclusion, among men participating in the HIM study, baseline seropositivity after 
natural infection with HPV 6, 11 and 16 was not associated with protection against subsequent 
type-specific genital infection, with a possible protective effect against persistent HPV 18 
infections. For HPV 16, a significantly higher risk of incident infection was observed among 
seropositive men. The effect of anti-HPV antibodies may be influenced by duration of the 
antibody response, time period between initial and subsequent genital infection, and overall 
antibody levels. These results highlight the importance of HPV prevention measures, such as 
vaccination, which are proven to protect against subsequent HPV infections and related genital 
diseases.  
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Table 2.1- Demographic characteristics of seronegative and HPV 6, 11, 16 and 18 seropositive HIM Study participants 
 HPV 6 HPV 11 HPV 16 HPV 18 
  Characteristics Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive 
Country         
  United States 1216 (96.4) 46 (3.6) 1249 (94.0)  80 (6.0) 1086 (88.6) 140 (11.4) 1209 (93.2) 88 (6.8) 
  Brazil 1173 (89.2) 142 (10.8) 1155 (83.1) 235 (16.9) 1047 (81.7) 234 (18.3) 1199 (87.0) 179 (13.0) 
  Mexico 1149 (90.2) 125 (9.8) 1077 (81.2) 250 (18.8) 1176 (91.7) 107 (8.3) 1170 (87.6) 166 (12.4) 
  p valuea  <0.0001  <0.0001  <0.0001  <0.0001 
Age         
  18-30 1723 (93.1) 127 (6.9) 1740 (88.2) 232 (11.8) 1655 (90.9) 165 (9.1) 1786 (91.8) 159 (8.2) 
  31-44 1354 (90.6) 140 (9.4) 1296 (83.8) 250 (16.2) 1225 (83.6) 241 (16.4) 1366 (88.3) 181 (11.7) 
  45-73 461 (90.9) 46 (9.1) 445 (84.3) 83 (15.7) 429 (85.1) 75 (14.9) 426 (82.1) 93 (17.9) 
  p valuea  0.0209  <0.0001  <0.0001  <0.0001 
Marital status         
  Single  1583 (92.6) 127 (7.4) 1606 (88.2) 214 (11.8) 1475 (87.9) 203 (12.1) 1612 (90.3) 174 (9.7) 
  Married/ 
Cohabitating 
1628 (91.3) 156 (8.7) 1555 (83.9) 298 (16.1) 1544 (87.6) 218 (12.4) 1648 (88.8) 208 (11.2) 
 Divorced/Separated 307 (91.6) 28 (8.4) 300 (85.7) 50 (14.3) 272 (82.4) 58 (17.6) 296 (85.3) 51 (14.7) 
  p valuea  0.3578  0.0016  0.0217  0.0209 
Race         
  Whites 1590 (93.3) 114 (6.7) 1587 (87.7) 223 (12.3) 1419 (85.2) 246 (14.8) 1606 (90.5) 169 (9.5) 
  African-Americans 547 (91) 54 (9.0) 561 (88.6) 72 (11.4) 486 (83.5) 96 (16.5) 547 (87.4) 79 (12.6) 
  Asian/Pacific 
Islander 
105 (98.1) 2 (1.9) 105 (93.8) 7 (6.3) 100 (92.6) 8 (7.4) 101 (93.5) 7 (6.5) 
  Mixed race/Others b 1236 (89.8) 141 (10.2) 1171 (81.9) 258 (18.1) 1254 (90.9) 125 (9.1) 1265 (87.9) 174 (12.1) 
  p valuea  <0.0001  <0.0001  <0.0001  0.0213 
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Table 2.1(Continued)    
 HPV 6 HPV 11 HPV 16 HPV 18 
  Characteristics Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive 
 
Education 
        
  ≤ 12 years 1689 (89.9) 189 (10.1) 1653 (83.8) 319 (16.2) 1622 (86.9) 244 (13.1) 1750 (88.8) 221 (11.2) 
  13-15 years 931 (95.0) 49 (5.0) 933 (91.3) 89 (8.7) 854 (89.9) 96 (10.1) 917 (90.9) 92 (9.1) 
  ≥16 years 895 (92.5) 73 (7.5) 875 (85.3) 151 (14.7) 813 (85.5) 138 (14.5) 888 (88.4) 117 (11.6) 
  p valuea  <0.0001  <0.0001  0.0113  0.1369 
 
Alcohol use 
        
  Non-drinkers 834 (89.8) 95 (10.2) 822 (85.0) 145 (15.0) 803 (86.9) 121 (13.1) 846 (87.9) 117 (12.1) 
  <0.5 drinks/day 1173 (91.9) 103 (8.1) 1133 (85.1) 199 (14.9) 1110 (88.3) 147 (11.7) 1169 (88.3) 155 (11.7) 
  0.5-2 drinks/day 817 (93.1) 61 (6.9) 813 (87.4) 117 (12.6) 760 (88.1) 103 (11.9) 832 (91.3) 79 (8.7) 
  >2 drinks/day 563 (92.9) 43 (7.1) 566 (87.3) 82 (12.7) 506 (85.6) 85 (14.4) 574 (89.4) 68 (10.6) 
  p valuea  0.0469  0.2322  0.3649  0.0649 
 
Cigarette smoking 
        
  Never 2059 (92.9) 158 (7.1) 2020 (87) 302 (13.0) 1912 (87.5) 272 (12.5) 2072 (90.2) 226 (9.8) 
  Former smoker 644 (91) 64 (9.0) 636 (85) 112 (15.0) 612 (86.9) 92 (13.1) 646 (86.8) 98 (13.2) 
  Current smoker 811 (90.3) 87 (9.7) 802 (84.4) 148 (15.6) 760 (86.8) 116 (13.2) 832 (88.5) 108 (11.5) 
  p valuea  0.0244  0.1118  0.8047  0.0302 
 
Circumcision 
        
  No 2152 (90.2) 233 (9.8) 2078 (83.2) 421 (16.8) 2045 (86.8) 310 (13.2) 2195 (88.0) 299 (12.0) 
  Yes 1386 (94.5) 80 (5.5) 1403 (90.7) 144 (9.3) 1264 (88.1) 171 (11.9) 1383 (91.2) 134 (8.8) 
  p valuea  <0.0001  <0.0001  0.2636  0.0016 
 
Sexual orientation 
        
  MSW 2664 (93.5) 186 (6.5) 2640 (88) 360 (12.0) 2504 (89.3) 300 (10.7) 2704 (91) 267 (9.0) 
  MSM 86 (76.8) 26 (23.2) 84 (72.4) 32 (27.6) 80 (71.4) 32 (28.6) 82 (70.7) 34 (29.3) 
  MSWM 325 (83.8) 63 (16.2) 312 (75.5) 101 (24.5) 291 (76.6) 89 (23.4) 328 (80.2) 81 (19.8) 
  p valuea  <0.0001  <0.0001  <0.0001  <0.0001 
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Table 2.1(Continued)    
 HPV 6 HPV 11 HPV 16 HPV 18 
  Characteristics Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive Seronegative Seropositive 
Lifetime female 
sexual partners 
        
  0-1 partners 764 (92.7) 60 (7.3) 487 (87.4) 70 (12.6) 483 (89.4) 57 (10.6) 518 (92.3) 43 (7.7) 
  2-9 partners 1171 (92.7) 92 (7.3) 1393 (86.6) 216 (13.4) 1362 (89.4) 162 (10.6) 1449 (90.8) 147 (9.2) 
 10-49 partners 1082 (92.6) 87 (7.4) 1080 (86.2) 173 (13.8) 987 (86.6) 153 (13.4) 1096 (88.5) 142 (11.5) 
  ≥50 partners 193 (88.9) 24 (11.1) 201 (87) 30 (13.0) 171 (80.7) 41 (19.3) 192 (85.3) 33 (14.7) 
  p valuea  0.2589  0.9058  0.0010  0.0041 
New female 
partners in past 3-6 
months 
        
  None 2020 (92.3) 169 (7.7) 1982 (86.6) 306 (13.4) 1898 (87.7) 265 (12.3) 2027 (89.5) 238 (10.5) 
 1 partner 809 (93.1) 60 (6.9) 804 (86.7) 123 (13.3) 768 (89.6) 89 (10.4) 835 (90.6) 87 (9.4) 
 ≥2 partners 389 (93.3) 28 (6.7) 392 (88.5) 51 (11.5) 343 (85.3) 59 (14.7) 395 (91.0) 39 (9.0) 
  p valuea  0.6271  0.5583  0.0838  0.4886 
Lifetime male 
sexual partners 
        
  None 2765 (93.6) 188 (6.4) 2745 (88.2) 366 (11.8) 2602 (89.6) 302 (10.4) 2808 (91.2) 270 (8.8) 
  1-9 partners 306 (87.4) 44 (12.6) 299 (80.2) 74 (19.8) 282 (81.5) 64 (18.5) 317 (85.9) 52 (14.1) 
 ≥10 partners 105 (70.0) 45 (30.0) 97 (62.2) 59 (37.8) 89 (61) 57 (39.0) 93 (59.6) 63 (40.4) 
  p valuea  <0.0001    <0.0001  <0.0001  <0.0001 
New male partners 
in past 3 months 
        
  None 3054 (92.7) 239 (7.3) 3015 (87) 450 (13) 2865 (88.6) 370 (11.4) 3100 (90.4) 329 (9.6) 
 1 partner 57 (77) 17 (23.0) 59 (72) 23 (28.0) 51 (67.1) 25 (32.9) 60 (72.3) 23 (27.7) 
 ≥2 partners 64 (72.7) 24 (27.3) 66 (70.2) 28 (29.8) 57 (66.3) 29 (33.7) 56 (60.9) 36 (39.1) 
  p valuea  <0.0001  <0.0001  <0.0001  <0.0001 
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Footnotes: 
Abbreviation: HPV, human papillomavirus; MSM, men who have sex with men; MSW, men who have sex with women; MSWM, men who  
have sex with women and men 
 
a - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of p-values, α = 0.05. 
b - Includes mixed race, American Indians, Alaska natives, Native Hawaiians or other races 
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Table 2.2a –HPV6, 11, 16 and 18 incidence proportions during 4 years follow-up in HIM Study  
Time of DNA 
detection 
HPV 6 HPV 11 HPV 16 HPV 18 
At riska N IP (95% CI) b At riska N IP (95% CI) b At riska N IP (95% CI) b At riska N IP (95% CI) b 
0-6 months 
  
              
Seronegative 2371 47 1.98 (1.42, 2.54) 2384 13 0.55 (0.25, 0.84) 2227 45 2.02 (1.44, 2.61) 2454 26 1.06 (0.65, 1.46) 
Seropositive 214 5 2.34 (0.31, 4.36) 393 0 0.00 (NA) 316 7 2.22 (0.59, 3.84) 298 0 0.00 (NA)  
7-12 months 
  
              
Seronegative 2615 53 2.03 (1.49, 2.57) 2681 22 0.82 (0.48, 1.16) 2443 52 2.13 (1.56, 2.70) 2717 32 1.18 (0.77, 1.58) 
Seropositive 233 6 2.58 (0.54, 4.61) 437 2 0.46 (0.18, 1.09) 364 5 1.37 (0.18, 2.57) 333 2 0.60 (0.23, 1.43) 
13-18 monthsc 
  
              
Seronegative 2539 58 2.28 (1.70, 2.87) 2607 14 0.54 (0.26,0.82) 2382 55 2.31 (1.71, 2.91) 2673 33 1.23 (0.82, 1.65) 
Seropositive 228 4 1.75 (0.05, 3.46) 434 1 0.23 (0.22, 0.68) 345 5 1.45 (0.19, 2.71) 322 5 1.55 (0.20, 2.90) 
19-24 months 
  
              
Seronegative 2436 29 1.19 (0.76, 1.62) 2528 15 0.59 (0.29, 0.89) 2249 60 2.67 (2.00, 3.33) 2554 23 0.90 (0.53, 1.27) 
Seropositive 201 4 1.99 (0.06, 3.92) 406 3 0.74 (0.09, 1.57) 337 17 5.04 (2.71, 7.38) 319 4 1.25 (0.03, 2.48) 
25-30 months 
  
              
Seronegative 2258 33 1.46 (0.97, 1.96) 2376 10 0.42 (0.16, 0.68) 2089 28 1.34 (0.85, 1.83) 2417 22 0.91 (0.53, 1.29) 
Seropositive 194 3 1.55 (0.19, 3.28) 401 2 0.50 (0.19, 1.19) 292 9 3.08 (1.10, 5.06) 279 0 0.00 (NA) 
31-36 months 
  
              
Seronegative 2215 32 1.44 (0.95, 1.94) 2329 12 0.52 (0.22, 0.81) 2031 44 2.17 (1.53, 2.80) 2351 18 0.77 (0.41, 1.12) 
Seropositive 205 4 1.95 (0.06, 3.84) 392 2 0.51 (0.20, 1.22) 297 10 3.37 (1.32, 5.42) 303 3 0.99 (0.12, 2.10) 
37-42 months 
  
              
Seronegative 1938 24 1.24 (0.75, 1.73) 2058 18 0.87 (0.47, 1.28) 1741 32 1.84 (1.21, 2.47) 2072 16 0.77 (0.40, 1.15) 
Seropositive 157 2 1.27 (0.48, 3.03) 347 7 2.02 (0.54, 3.50) 242 10 4.13 (1.62, 6.64) 275 4 1.45 (0.04, 2.87) 
43-48 months 
  
              
Seronegative 1716 31 1.81 (1.18, 2.44) 1863 4 0.21 (0.00, 0.42) 1581 32 2.02 (1.33, 2.72) 1846 16 0.87 (0.44 , 1.29) 
Seropositive 158 1 0.63 (0.60, 1.87) 321 0 0.00 (NA) 245 6 2.45 (0.51, 4.38) 248 3 1.21 (0.15,  2.57) 
>48 months 
  
              
Seronegative 559 12 2.15 (0.95, 3.35) 623 3 0.48 (1.97, 2.32) 526 14 2.66 (1.29, 4.04) 628 14 2.23 (1.07, 3.38) 
Seropositive 37 1 2.70 (2.52, 7.93) 93 0 0.00 (NA) 55 1 1.82 (1.70, 4.37) 64 1 1.56 (1.48, 4.60) 
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Footnotes –  
Abbreviations: HPV-human papilloma virus; IP-Incidence proportion, CI-confidence interval; NA-Not Applicable, Sero- = Seronegative, Sero+ = Seropositive 
a - No. at risk was defined as number of men followed till the stated duration, who were HPV DNA negative for particular HPV type at the beginning of time interval 
b - Percentage was defined as the number of incident infection over the number of participants at risk that occurred at each time interval 
c - Participants who were late (1st follow-up visit after six months), were included in successive time interval based on the visit date, which led to higher numbers for second 
follow-up period. 
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Time of DNA 
detection 
HPV 6 HPV 11 HPV 16 HPV 18 
At 
riska N IP (95% CI) b 
At 
riska N IP  (95% CI) b 
At 
riska N IP  (95% CI) b 
At 
riska N IP (95% CI) b 
    
            
7-12 months 
   
            
Seronegative 2012 11 0.55 (0.22, 0.87) 2035 7 0.34 (0.09, 0.60) 1885 15 0.80 (0.39, 1.20) 2079 8 0.38 (0.12, 0.65) 
Seropositive 174 1 0.57 (0.55, 1.70) 332 0 0.00 (NA) 277 2 0.72 (0.28, 1.72) 256 0 0.00 (NA) 
13-18 monthsc 
   
            
Seronegative 2539 22 0.87 (0.51, 1.23) 2571 4 0.16 (0.00, 0.31) 2389 26 1.09 (0.67, 1.50) 2657 16 0.60 (0.31, 0.90) 
Seropositive 233 2 0.86 (0.33, 2.04) 431 0 0.00 (NA) 344 2 0.58 (0.22, 1.38) 315 0 0.00 (NA) 
19-24 months 
   
            
Seronegative 2464 17 0.69 (0.36, 1.02) 2530 8 0.32 (0.10, 0.53) 2302 28 1.22 (0.77, 1.66) 2561 18 0.70 (0.38, 1.03) 
Seropositive 202 1 0.50 (0.47, 1.46) 398 0 0.00 (NA) 337 4 1.19 (0.03, 2.34) 319 1 0.31 (0.30, 0.93) 
25-30 months 
   
            
Seronegative 2283 16 0.70 (0.36, 1.04) 2380 5 0.21 (0.03, 0.39) 2120 13 0.61 (0.28, 0.95) 2435 10 0.41 (0.16, 0.66) 
Seropositive 199 2 1.01 (0.38, 2.39) 402 0 0.00 (NA) 305 3 0.98 (0.12, 2.09) 283 0 0.00 (NA) 
  
   
            
31-36 months 
   
            
Seronegative 2248 12 0.53 (0.23, 0.84) 2340 5 0.21 (0.03, 0.40) 2061 13 0.63 (0.29, 0.97) 2371 6 0.25 (0.05, 0.46) 
Seropositive 207 1 0.48 (0.46, 1.43) 395 1 0.25 (0.24, 0.75) 311 3 0.96 (0.12, 2.05) 303 0 0.00 (NA) 
37-42 months 
   
            
Seronegative 1956 6 0.31 (0.06, 0.55) 2062 3 0.15 (0.02, 0.31) 1773 15 0.85 (0.42, 1.27) 2082 7 0.34 (0.09, 0.58) 
Seropositive 160 0 0.00 (NA) 353 1 0.28 (0.27, 0.84) 252 4 1.59 (0.04, 3.13) 275 0 0.00 (NA) 
43-48 months 
   
            
Seronegative 1737 12 0.69 (0.30, 1.08) 1869 4 0.21 (0.00, 0.42) 1600 9 0.56 (0.20, 0.93) 1857 6 0.32 (0.06, 0.58) 
Seropositive 159 0 0.00 (NA) 321 0 0.00 (NA) 248 2 0.81 (0.31, 1.92) 252 0 0.00 (NA) 
>48 months 
   
            
Seronegative 569 4 0.70 (0.02, 1.39) 627 1 0.16 (0.15, 0.47) 536 1 0.19 (0.18, 0.55) 634 3 0.47 (0.06, 1.01) 
Seropositive 37 0 0.00 (NA) 95 0 0.00 (NA) 60 1 1.67 (1.57, 4.91) 65 1 1.54  (1.45, 4.53) 
 
Table 2.2b –   HPV 6, 11, 16 and 18 incident persistent infections during 4 years follow-up in HIM Study  
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Footnotes –  
Abbreviations: HPV, human papilloma virus; CI, confidence interval; NA, Not Applicable 
a - No. at risk was defined as number of men followed till the stated duration, who were HPV DNA negative or positive for particular HPV type at the beginning of each time 
interval  
b - Percentage was defined as the number of incident infection over the number of participants at risk that occurred at each time interval 
c - Participants who were late (1st follow-up visit after six months), were included in successive time interval based on the visit date, which led to higher numbers for second 
follow-up period. 
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Table 2.3 - Crude and adjusted hazard ratios (HR) according to sero-status for incident HPV 6, 11, 16 and 18 infections among 
HIM Study participants 
 No. of men No. of infections Crude HR and 95% CI Adjusted HR and 95% CI 
Incident 
infection 
    
HPV 6     
Seronegative 3105 319 1.00  1.00 
Seropositive 283 30 1.08 (0.74, 1.56) 0.91 (0.56, 1.48)
a
 
HPV 11     
Seronegative 3132 111 1.00 1.00 
Seropositive 513 17 0.92 (0.55, 1.54) 0.80 (0.44, 1.45)
b
 
HPV 16     
Seronegative 2912 362 1.00 1.00 
Seropositive 420 70 1.40 (1.08, 1.81) 1.37 (1.01, 1.86)
c
 
HPV 18     
Seronegative 3202 200 1.00 1.00 
Seropositive 391 22 0.92 (0.59, 1.43) 0.90 (0.531, 1.57)
d
 
6 month 
persistent 
infection 
    
HPV 6     
Seronegative 3105 100 1.00  1.00 
Seropositive 283 7 0.80 (0.37,  1.73) 0.98 (0.39, 2.46)
e
 
HPV 11     
Seronegative 3132 37 1.00 1.00 
Seropositive 513 2 0.32 (0.08, 1.34) 0.31 (0.04, 2.30)
f
 
HPV 16     
Seronegative 2912 120 1.00 1.00 
Seropositive 420 21 1.26 (0.79, 2.01) 1.39 (0.80, 2.41)
g
 
HPV 18     
Seronegative 3202 74 1.00 1.00 
Seropositive 391 2 0.22 (0.06, 0.91) 0.19(0.03 1.37)
h
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Footnotes: HPV- Human Papillomavirus, HR- Hazard ratios 
a - Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time 
varying). 
b - Adjusted for marital status, race, lifetime female sexual partners (time varying), and new male partners in past 6-12 months (time varying). 
c - Adjusted for age, marital status, lifetime female sexual partners (time varying), lifetime male sexual partners (time varying), and new female 
partners in past 6-12 months (time varying).  
d - Adjusted for country, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time varying). 
e - Adjusted for age, alcohol use, new female partners in past 6-12 months (time varying) and frequency of sexual intercourse with female partners 
in past 6-12 months. 
f - Adjusted for age, alcohol use, new female partners in past 6-12 months (time varying) and new male partners in past 6-12 months (time 
varying) 
g - Adjusted for age, country, lifetime male sexual partners (time varying) and new female partners in past 6-12 months (time varying) 
h - Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time 
varying). 
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Table 2.4 - Crude and adjusted hazard ratios (HR) stratified by sexual orientation for incident 
HPV 16 and 18 infections among HIM Study participants 
   
  HPV 16 HPV 18 
  
At 
risk N Crude HR Adjusted HR 
At 
risk N Crude HR Adjusted HR 
Incident 
infections 
 
  
 
  
 
  
 
  
MSW 
 
  
 
  
 
  
 
  
Seronegative 2204 269 1.0 1.0 2419 138 1.0 1.0 
Seropositive 261 42 1.37 (0.99, 1.90) 1.31(0.90,1.93)a  242 11 0.82 (0.45, 1.52) 1.01 (0.51, 2.01)d 
  
 
  
 
  
 
  
 
  
MSWM 
 
  
 
  
 
  
 
  
Seronegative 268 47 1.0 1.0 305 27 1.0 1.0 
Seropositive 82 14 1.06 (0.58, 1.93) 0.88 (0.45, 1.73)b 73 7 1.12 (0.49, 2.56) 1.02 (0.41, 2.58)e 
  
 
  
 
  
 
  
 
  
MSM 
 
  
 
  
 
  
 
  
Seronegative 75 12 1.0 1.0 78 10 1.0 1.0 
Seropositive 27 6 1.33 (0.50, 3.55)  1.61 (0.58, 4.53)c 31 2 0.44 (0.09, 2.03) 0.98 (0.17, 5.67)
c
  
  
 
  
 
  
 
  
 
  
Six month 
persistent 
infections 
 
  
 
  
 
  
 
  
MSW 
 
  
 
  
 
  
 
  
Seronegative 2204 93 1.0 1.0 2419 53 1.0 1.0 
Seropositive 261 15 1.42 (0.82, 2.44) 1.46 (0.79, 2.73)f 242 1 0.19 (0.03, 1.41)  0.25 (0.03,1.84)
i
 
  
 
  
 
  
 
  
 
  
MSWM 
 
  
 
  
 
  
 
  
Seronegative 268 13 1.0 1.0 305 9 1.0 1.0 
Seropositive 82 3 0.83 (0.24, 2.93)  0.85 (0.24, 3.00)
g
 73 1 0.49 (0.06, 3.84)  0.51 (0.06,  4.03)
h
 
  
 
  
 
  
 
  
 
  
MSM 
 
  
 
  
 
  
 
  
Seronegative 75 5 1.0 1.0 78 1 1.0 1.0 
Seropositive 27 1 0.54 (0.06, 4.60) 0.58 (0.07, 4.97)
h
 31 0 NE NE 
      Footnotes: 
HPV- Human Papillomavirus, HR- Hazard ratios, MSW- Men who have sex with women, MSWM- Men who have sex with women and men, MSM- Men 
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who have sex with men 
 a-Adjusted for  race, alcohol use, lifetime female partners (time varying) and new female partners in past 6-12 months(time varying) 
b-Adjusted for marital status, alcohol use, new female partners in past 6-12 months(time varying) and new male partners in past 6-12 months(time varying)  
 c - Adjusted for new male partners in past 6-12 months(time varying)  
  d-  Adjusted for marital status, alcohol use, new female partners in past 6-12 months(time varying) and frequency of sexual intercourses in past 6-12 
months(time varying) 
e-  Adjusted for age, new male partners in past 6-12 months(time varying) and frequency of sexual intercourse with female partners in past 6-12 
months(time varying) 
      f-Adjusted for age, country, and new female partners in past 6-12 months(time varying)  
 g- Adjusted for country 
h-  Adjusted for age 
i-  Adjusted for marital status, lifetime female partners(time varying) and new female partners   in past 6-12 months(time varying) 
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Table 2.5: Crude and adjusted hazard ratios (HR) according to seropositive for any four HPV types (HPV 6, 
11, 16 and 18) compared to seronegative for all four types infections among men in the HIM study 
 No. of men No. of 
infections 
Crude HR and 95% CI Adjusted HR and 95% CI 
Incident infection     
HPV 6     
Seronegative
a
 2663 240 1.00  1.00 
Seropositive
b
 1082 109 1.12 (0.90, 1.41) 1.08(0.81, 1.43)
c
 
HPV 11     
Seronegative
a
 2858 88 1.00 1.00 
Seropositive
b
 1164 40 1.12 (0.77, 1.63) 0.89 (0.55, 1.42)
d
 
HPV 16     
Seronegative
a
 2609 307 1.00 1.00 
Seropositive
b
 1062 125 1.01 (0.82, 1.24) 1.08 (1.84, 1.39)
e
 
HPV 18     
Seronegative
a
 2803 157 1.00 1.00 
Seropositive
b
 1158 65 1.00 (0.75, 1.34) 1.09 (0.77, 1.54)
f
 
6 month persistent 
infection 
    
HPV 6     
Seronegative
a
 2663 83 1.00  1.00 
Seropositive
b
 1082 24 0.72 (0.46,  1.13) 0.82 (0.48, 1.40)
g
 
HPV 11     
Seronegative
a
 2858 30 1.00 1.00 
Seropositive
b
 1164 9 0.73 (0.35, 1.54) 0.49 (0.17, 1.44)
h
 
HPV 16     
Seronegative
a
 2609 101 1.00 1.00 
Seropositive
b
 1062 40 0.98 (0.68, 1.41) 1.27(0.83, 1.92)
i
 
HPV 18     
Seronegative
a
 2803 64 1.00 1.00 
Seropositive
b
 1158 12 0.45 (0.24, 0.84) 0.42 (0.19, 0.93)
j
 
 
Footnote: HPV- Human Papillomavirus, HR- Hazard ratios 
a – Seropositive for any of the 4 HPV types (HPV 6, 11, 16 and 18) 
b – Seronegative for all 4 HPV types (HPV 6, 11, 16 and 18) 
c- Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time 
varying). 
d- Adjusted for country, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time varying). 
e - Adjusted for country, lifetime female sexual partners (time varying), lifetime male sexual partners (time varying), and new female 
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 partners in past 6-12 months (time varying). 
f- Adjusted for marital status, alcohol use, lifetime male sexual partners (time varying), and new female partners in past 6-12 months (time 
varying). 
g - Adjusted for age, alcohol use and new female partners in past 6-12 months (time varying). 
h - Adjusted for new female partners in past 6-12 months (time varying) and new male partners in past 6-12 months (time varying). 
i - Adjusted for age, country and new female partners in past 6-12 months (time varying) 
j - Adjusted for marital status, lifetime female sexual partners (time varying), and new female partners in past 6-12 months (time varying). 
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Figure 2.1 - Kaplan-Meier curves for acquisition of incident HPV 6, 11, 16, and 18 infections by serostatus among men in the HIM 
Study 
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Footnotes: 
Serum status: Solid line = Seronegative subjects, Dashed line= Seropositive subjects 
P values were determined using the log-rank test and denote differences across the entire follow-up period, by serum status. Values < .05  
are considered statistically significant 
Median failure times were 47.6 months (HPV 6), 48.6 months (HPV 11), 47.9 months (HPV 16) and 48.5 months (HPV 18).  
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Figure 2.2 - Kaplan-Meier curves for acquisition of six-month persistent HPV 6, 11, 16, and 18 infections by serostatus among men 
in the HIM Study 
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Footnotes: 
Serum status: Solid line = Seronegative subjects, Dashed line= Seropositive subjects  
P values were determined using the log-rank test and denote differences across the entire follow-up period, by serum status. Values < .05  
are considered statistically significant 
Median failure times were 47.8 months (HPV 6), 48.7 months (HPV 11), 48.0 months (HPV 16) and 48. 6 months (HPV 18). 
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MANUSCRIPT TWO 
 
Introduction:  
          Human Papillomavirus (HPV) infection is one of the most common sexually transmitted 
infections in men and women (147). The Human Papillomavirus Infection in Men (HIM) Study 
was among the first to report the natural history of genital HPV infection among men (147, 148). 
In this study, average duration of a genital HPV infection was ~7.5 months for any HPV 
infection and 12.2 months for HPV 16 infection (147). After initial clearance (≥ 12 month time 
without detection of HPV DNA), individuals were susceptible for recurrence/redetection of HPV 
infection with the same HPV type. Recurrent HPV infection is an important component of the 
natural history of these infections and may help to elucidate the anogenital HPV prevalence 
observed among men in numerous studies (147, 139-152).   
          No studies have evaluated HPV recurrence in men and only a few have examined the 
recurrence of cervical HPV infection among women. In studies among women, 18.1-19.5% of 
HPV infections were redetected (153-157). High risk sexual behaviors, such as having multiple 
sexual partners and new sexual partners, were reported as some of the most important risk factors 
associated with redetection of cervical HPV infection (153, 157). However, sexual behavior did 
not explain all the infection recurrences observed in women.  
          In the current study, we assessed recurrence of nine HPV vaccine types (HPV 6, 11, 16, 
18, 31, 33, 45 52 and 58) in the HIM Study cohort (n= 4,123).  Our objective was to estimate 
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type-specific recurrence of genital HPV infections and investigate factors associated with 
recurrence among men.  
Methods: 
Study population 
          The HPV Infection in Men (HIM) Study is a study of the natural history of HPV among 
men in Tampa, Florida (U.S.), São Paulo (Brazil), and Cuernavaca (Mexico). Detailed methods 
and recruitment of study participants has been described previously (148). Briefly, healthy men 
from each study site were followed every six months for a median follow-up time of four years. 
Eligibility criteria for the participants were : i) 18–70 years of age; ii) residents of one of the  
study sites; iii) no previous diagnosis of penile or anal cancers; iv) no previous diagnosis of 
genital or anal warts; v) no symptoms of a sexually transmitted infection (STI) and not receiving 
treatment for an STI; vi) not participating in an HPV vaccine study; vii) no history of HIV or 
AIDS; viii) no history of imprisonment, homelessness, or drug treatment during the past six 
months; and ix) willing to comply with 10 scheduled visits every six months for four years with 
no plans to relocate during that time. Questionnaires were administered using computer-assisted 
self-interviewing (CASI) at baseline and each follow-up visit to obtain extensive sexual history 
and health information. All eligible participants provided signed informed consent, and approval 
was obtained from the human subjects committees of the University of South Florida (Tampa, 
FL), Ludwig Institute for Cancer Research (São Paulo, Brazil), Centro de Referencia e 
Treinamento em Doencas Sexualmente Transmissíveis e AIDS (São Paulo, Brazil), and Instituto 
Nacional de Salud Publica de Mexico (Cuernavaca, Mexico). 
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External genital HPV DNA samples 
          Genital cell samples from the coronal sulcus/glans penis, penile shaft, and scrotum were 
collected with three prewetted Dacron swabs, which were later combined to form a single sample 
(147, 148). Specimens were stored at -80°C, until analyses. The QIAamp DNA Blood Mini Kit 
(QIAGEN) was used to extract DNA and HPV DNA tests were performed using PCR 
amplification of the L1 gene fragment of HPV. Thirty seven different types of genital HPV were 
detected with use of the Roche Linear Array assay for HPV genotyping (158). Human β-globin 
was tested to assess specimen adequacy, with an overall β-globin positivity of 98%.  
Statistical analysis 
          The nine HPV types (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) in the recently approved 
nonavalent HPV vaccine were included in this analysis (159). Participants with prevalent HPV 
infections at baseline or an incident infection during the follow-up period were eligible for 
inclusion in the study. Participants who were HPV DNA negative throughout the entire study 
period, those with prevalent infections that persisted throughout the entire study period or 
incident infections that persisted throughout the remaining follow-up time, and participants who 
dropped out of the study before infection clearance were excluded from the analysis (Figure 3.1). 
Two different analyses were carried out: 1) individual HPV type analysis for each of the nine 
genotypes (infection-level type-specific analysis), and 2) grouped analyses (recurrent infection 
vs. non-recurrent infection with any of the 9 vaccine types). Recurrences assessed in both of 
these analyses were genotype concordant (type-specific).  For example, after clearance of HPV 
16 infection, recurrence of HPV 16 was assessed in the analyses. 
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          In individual HPV type (type-specific) analyses, infections were categorized into two 
groups: a) infections that were first observed as incident and b) infections observed as prevalent 
at the baseline visit. Both these groups were further categorized by infection duration; transient 
(observed at one visit only) and persistent (infection with duration of > 6 months). Infection 
recurrence was defined as reappearance/redetection of DNA of the same HPV genotype after two 
successive DNA-negative tests at clinical visits scheduled at 6-month intervals (>12 months 
duration). Figure 1 describes the study participants excluded and included in this analysis and 
definitions of the analytical groups. 
          For each HPV genotype, the proportion of infections that recurred among individuals with 
a prior incident or prior prevalent infection was calculated. Visit-specific questionnaire data 
corresponding to the two successive 6 month study visits following the last visit when that 
specific HPV DNA was detected (12-month at risk period for recurrence) were utilized in 
analyses for men whose infections did not recur. For men whose infections did recur, 
questionnaire data from the visit where the recurrence was observed (as behavior was inquired 
for the prior 6 months) and data reported on the visit prior to the recurrence (total time period up 
to 12 months prior to the recurrence) were utilized in analyses. Variables of interest for these 
analyses included sexual behavior, tobacco, alcohol use, and factors previously shown to be 
associated with genital incidence and prevalence in the HIM Study cohort (147, 148). 
          Grouped analysis was carried out to increase the power to assess associations between 
overall recurrence and related risk factors. If individuals had recurrent infection of any of the 9 
HPV types; they were grouped as “Recurrent infections for any type”. Individuals in the “Non-
recurrent infections” group did not have recurrences of any of the 9 HPV types. Subjects were 
further categorized into three groups: i) only incident infection with any of the nine types ii) only 
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prevalent infection with any of the nine types, and iii) a combination of prevalent and incident 
infection with any of the nine types. Demographic characteristics for these groups were 
compared using Chi-square tests with Monte Carlo estimation of exact p-values.  In the grouped 
analysis men who had multiple HPV infections, “at risk period for recurrence” differed across 
infections in men. Therefore, we characterized individual behavior based on participants’ overall 
pattern of responses throughout the study follow-up for sexual behavior, tobacco, and alcohol 
use questions. Logistic regression was utilized to evaluate the association between these 
variables and infection recurrence. Behavioral factors, along with demographic variables, were 
evaluated in adjusted models.  Selection of variables for inclusion in final model was based on 
the Akaike information criteria (AIC) values. 
Results: 
          Genital DNA samples were available for 4,123 participants of the HIM study at baseline. 
For type-specific analyses, subjects were excluded (HPV6 = 621, HPV11 =171, HPV16 = 762,   
HPV18 = 300,   HPV31 = 226,   HPV33 = 76,   HPV45 = 268,   HPV52 = 486, and HPV58 = 
292) if they were HPV DNA negative throughout the study follow-up, had persistent infection 
throughout the duration of their follow-up time or dropped out before clearing the infection.  
After these exclusions, 1,119 men with incident and 1,106 men with prevalent infections of one 
or more of the nine vaccine type HPVs were included in analyses. Median duration of follow-up 
was 3.7 years (range 0.4-7.4 years, mean 3.6 years, IQR 3.4-4.0).  
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A) Individual HPV type recurrence  
          Overall, men whose initial infections were prevalent had higher recurrences compared to 
men with initial incident infections (Figure 3.2). Recurrence proportions and factors associated 
with recurrence of prevalent and incident infections are as follows.  
Prevalent infections 
          Men with prior transient prevalent infections had recurrences ranging from 3.9%-31.2%, 
while men with prior persistent prevalent infections had recurrence ranging from 10.8%-36.8%. 
Among men with a prior transient prevalent infection, HPV 52 infection had the highest rate of 
recurrence (31.2%), followed by HPV 45 (22.9%), HPV 58 (21.4%), HPV 6 (19.8%), and HPV 
16 (19.6%) [Table 3.1a].  Among men with a prior persistent prevalent infection, HPV 45 had 
the highest rate of recurrence (36.8%), followed by HPV 52 (32.4%), HPV 16 (23.5%), and 
HPV6 (21.9%). Overall, persistent prevalent infections had higher recurrences compared to 
prevalent infections that were initially transient. The average cleared time between the initial 
prevalent infection (regardless of whether it was transient or persistent) and the recurrent 
infection was 20.2 months for HPV 6, 17.2 months for HPV 11, 21.5 months for HPV 16, 18.7 
months for HPV 18, 26.2 months for HPV 31, 22.5 months for HPV 33, 22.1 months for HPV 
45, 25.4 months for HPV 52, and 21.3 months for HPV 58.  
Incident infections 
          Recurrence of infections that were detected first as incident infections ranged from 0.0%-
19.7% for transient incident infections compared to 0.0%-26.3% among men whose prior 
incident infections were persistent. Among men whose incident infections were initially 
transient, the highest rate of recurrence was for HPV 58 (19.7%), followed by HPV 52 (14.6%), 
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HPV 18 (12.6%) and HPV 16 (11.8%) [Table 3.1b]. Among men whose prior incident infections 
were persistent, the highest recurrence was observed for HPV 11 (26.3%), followed by HPV 52 
(24.5%), HPV18 (17.6%) and HPV 45 (13.6%). Similar to what was observed among prevalent 
genital HPV infections, incident infections that were persistent had higher rates of recurrence 
compared to incident infections that were transient.  The average time between clearance of the 
incident infection (regardless of whether it was transient or persistent) and detection of the 
recurrence was 16.8 months (HPV 6), 18.2 months (HPV 11), 18.6 months (HPV 16), 17.4 
months (HPV 18), 18.7 months (HPV 31), 19.1 months (HPV 33), 21.3 months (HPV 45), 18.9 
months (HPV 52), and 15.2 months (HPV 58).  
Factors associated with genital HPV infection recurrence 
          Sexual behavior variables were consistently associated with recurrence of infection, 
regardless of whether the initially detected infection was prevalent or incident. Among men with 
initial prevalent infections, HPV 6 infection recurrence was significantly associated with having 
>=2 new female partners in previous 6-12 months (Table 3.2a). HPV 16 recurrence was 
associated with higher frequency of sexual intercourse with female partners (>30 times) in the 
past 6-12 months. For HPV 31, men who reported having a new female sexual partner had higher 
rates of recurrence (38.5%), compared to men who did not report a new sexual partner (Table 
3.2b). Recurrence of HPV 58 was highest among men consuming <0.5 drinks of alcohol per day.   
          Among men whose initially detected infections were incident, having one or more new 
male sexual partners in the previous 6-12 months was significantly associated with higher 
recurrence of HPV 16 infections (p= 0.01, Table 3.3a). Additionally, current smokers had the 
highest proportion of HPV 16 recurrence (18.6%), although this association did not reach 
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statistical significance (p= 0.06). Significantly higher rates of HPV 52 recurrence were observed 
among former smokers (27.3%) compared to current smokers (p= 0.04, Table 3.3b). HPV 58 
recurrence was associated with higher frequency of sexual intercourse (>30 times) with female 
partners in past 6-12 months, but this association did not reach statistical significance (p = 0.09).  
B) HPV infection recurrence in grouped analysis  
          In grouped analyses, numbers of men included in each of the three groups were, 635 (only 
incident infection of any of the nine types), 641 (only prevalent infection of any of the nine 
types), and 261 (mixed infections or combination of prevalent and incident infections) [Figure 
3.3].  In this analysis, 13.4% men with prior incident infections had recurrence of any of the nine 
HPV types. In comparison, 24.6% of men with prior prevalent infections had recurrence of any 
of the nine HPV types. The highest rates of recurrence were observed among men who in the 
past had a combination of both an incident and prevalent infections of different types (43%). 
White men had the highest proportion (17.6%) of incident infections that recurred (p= 0.036, 
Table 3.4). Recurrence of incident infections was also higher among men with a greater number 
of lifetime male sexual partners (p= 0.012) and a greater number of new male partners (p= 
0.011). Among men with combination of incident/prevalent infections, men with circumcision 
had higher recurrence compared to the uncircumcised men (p= 0.011). Among men with initially 
prevalent infections, none of the considered variables were significantly associated with infection 
recurrence. 
          In logistic regression models (Table 3.5) utilizing overall behavior of the participants 
during the follow-up period, statistically significant associations (adjusted odds ratios= aOR) 
were observed with lifetime number of male sexual partners (aOR = 2.40, 95% CI 1.19-4.84) and 
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number of new male sexual partners (aOR 2.35, 95% CI 1.16-4.74) among men who previously 
only had an incident infection detected.  Among men with a prior prevalent infection, moderate 
alcohol consumption (0.5-<1.5 drinks per day) was significantly associated with a higher risk of 
recurrence (aOR= 1.59, 95% CI 1.01, 2.53) compared to mild alcohol consumption (<0.5 
drinks/day). Among men with combination of prior incident and prevalent infections, none of the 
considered variables yielded statistically significant results.  
Discussion:  
          This is the first study to report recurrence of nine vaccine type (HPV 6, 11, 16, 18, 31, 33, 
45, 52, and 58) genital HPV infections among men. Our results indicate that as many as 31.2% 
of genital HPV infections recur with the same type, with higher rates of recurrence for oncogenic 
HPV types (HPV 16, 18, 45, 52, and 58).  
           In the current analysis, a higher number of new male sexual partners was consistently 
associated with higher rates of recurrence of incident infections in both type-specific (HPV 16) 
analyses as well as grouped analyses. Other high-risk sexual behaviors (higher number of new 
female partners and frequency of sexual intercourse) were also associated with higher rates of 
recurrence of initially prevalent HPV 6, 16 and 31 infections. Recurrence significantly differed 
by smoking and alcohol use only for HPV types 16, 52, and 58. As no prior study has described 
genital HPV recurrence among men, it is unclear with the rates reported here are unique to the 
cohort, or geographic regions of study.   
          Among women, only a few studies have examined the recurrence of cervical HPV 
infection. One study found that 19.4% of incident infections of multiple genotypes were 
redetected within a year (154). A study examining specific HPV types reported a range of 0-16% 
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recurrent HPV infections, with up to 11% of HPV 16 infections reappearing after 3 years (155). 
A study by Moscicki et al. observed that HPV 16 DNA was redetected in 18.1% women after 
clearance of initial infection (156). This study also reported that having one or more sexual 
partners (aOR= 2.90, 95% CI 1.22, 6.90) and having a new sexual partner in the past eight 
months (aOR= 1.1, 95% CI 1.02, 1.19) were associated with increased risk of redetection (156). 
Another study observed an association between recurrence and having new sexual partners with 
relative risk (RR) estimate of 3.7 (95% CI=1.1–13.8) for all HPV types included in the analysis 
(153). These results are comparable to our findings of recurrence of HPV infection among men. 
In contrast, lower rates of recurrence were observed (7.7% women with intervening negative 
results and 2.7% women with definite clearance) in a study that included multiple carcinogenic 
HPV types (157).  
          We observed higher rates of recurrence among participants with prior prevalent infections 
and prior persistent infections (either incident or prevalent). Baseline prevalent infections had a 
relatively longer observation period to allow for clearance and re-detection compared infections 
detected as incident at some point in the follow-up period. As a result, there were more 
recurrence events and greater power to assess associations with infections initially detected as 
prevalent. This may partially explain the higher rates of recurrence for prior prevalent infections. 
It is also likely that individuals with pre-existing infections had high risk sexual behavior and as 
a result were at higher risk of re-acquiring of HPV infections. Similarly, individuals with 
persistent infections may have engaged in high risk sexual behaviors, but due to the small sample 
size, we were unable to carry out separate analyses comparing transient and persistent infections 
for sexual behavior variables.  
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          There are three possible explanations for observed rates of HPV infection recurrence: a) 
sexual exposure from the same partner who has not cleared the infection; b) exposure to a new 
partner who is infected with the same HPV type; and c) reactivation of latent infections. Our 
results show that new male partners, new female partners, and higher numbers of lifetime sexual 
partners lead to higher genital HPV infection recurrence. We do not, however, have information 
to differentiate whether the recurrence was acquired from a new partner or from the same 
partner. Partner studies as well as perhaps evaluation of HPV status with next generation 
sequencing are needed to shed light on the origin of the recurrent infections. However, intra-
typic variant analysis may not identify the source of infection, as specific HPV variants are more 
prevalent in a particular geographic area (160-162); thus probability of infection from a new 
source is highest for the prevalent variant circulating in the community. In addition, current 
methods can not differentiate between latent and newly acquired infections (163). Thus, analysis 
of recurrent infection presents a number of challenges and logistic issues.   
          Strengths of this study include large sample size, multinational nature of the cohort, and 
long follow-up time. Additionally, standard and robust HPV DNA genotyping measures were 
utilized (164-168).  Furthermore, we carefully assessed behavior during the intervening cleared 
period (susceptibility period for infection re-acquisition). The study also had several limitations 
that may have affected our results. We did not have information regarding HPV infection status 
of participants prior to the study start, therefore it is likely that participants may have had 
acquired and cleared infections prior to entering the study. Obtaining data for prior HPV DNA 
status is challenging as significant cost and resources are required to obtain this information, 
especially among men who were sexually active for a long time.  There is also a possibility of 
existing latent infection prior to study start or during the follow-up being detected as another 
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infection (163, 169-172). Latency of HPV is proposed based on the animal model whereby HPV 
is retained in a latent state in the basal epithelial stem cell pool (163).  Current HPV DNA 
detection methods may not be sensitive enough to detect low viral load of latent infections (169-
171) and re-activation of latent infection is less likely in immune competent subjects (as in the 
HIM study). Future studies are needed to further elucidate the latency of HPV infections in men 
and women. 
          Misclassification of HPV infection status is also a possibility. Low viral load and long 
period of time between the initial infection and assessment of HPV DNA may lead to 
misclassification of HPV infection status. However, such misclassification should play a very 
minor role in analyses, considering the robust methods used for HPV DNA detection (164-168). 
We did not have a sufficient number of recurrent infections to adequately power our individual 
type-specific analyses, especially for less common HPV types (e.g. HPV 11, 31, 33). We 
attempted to address this issue in our grouped analyses of all nine HPV types. Furthermore, 
subjects excluded from the analysis did not differ significantly from study participants for sexual 
behavior and other important demographic variables.   
          In conclusion, men are susceptible to genital HPV infection recurrence, with up to 31% of 
prevalent and 20% of incident infections recurring over time. Recurrence of HPV infection 
among men may be influenced by high-risk sexual behavior; including higher numbers of new 
sexual partners and lifetime sexual partners. Given the complexity of analyzing recurrence of 
HPV infections, future studies are needed to further understand the role of HPV recurrence in the  
etiology of HPV associated diseases.
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            Figure 3.1: Outline for tracking recurrent infections 
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Footnote: In examples, 0 = HPV DNA-negative status, 1 = HPV DNA-positive status 
 
Total numbers of excluded subjects according to HPV types were: HPV6 = 621, HPV11 =171, HPV16 = 762,   
 HPV18 = 300,   HPV31 = 226,   HPV33 = 76,   HPV45 = 268,   HPV52 = 486, and HPV58 = 292.  
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Figure 3.2: Proportion of recurrence infection among total prevalent and incident 
infections for HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 among men in USA, Brazil and 
Mexico in the HIM study. 
Footnotes: 
Abbreviation: HPV, human papillomavirus. 
Incident Recurrent: Incident infections (either transient or persistent) that cleared (2 successive negative 
DNA results) and then recurred during the median follow-up time of 48 months. 
Prevalent Recurrent
: 
 Prevalent infections (either transient or persistent) that cleared (2 successive 
negative DNA results) and then recurred during the median follow-up time of 48 months 
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Table 3.1a: Proportion of recurrent infections among men with a prior prevalent HPV 6, 
11, 16, 18, 31, 33, 45, 52 and 58 infections. 
HPV types Total 
prevalent 
infections 
Transient Prevalenta infections Persistent Prevalentb infections 
Recurrent
c 
/ 
Total 
transient 
infections 
Proportion (%) Recurrent
d 
/ 
Total persistent 
infections 
Proportions 
(%) 
HPV 6 260 29/146 19.86 25/114 21.93 
HPV 11 58 1/26 3.85 6/32 18.75 
HPV 16 282 26/133 19.55 35/149 23.50 
HPV 18 103 10/57 17.54 9/46 19.57 
HPV 31 81 8/44 18.18 4/37 10.81 
HPV 33 25 1/13 7.69 2/12 16.67 
HPV 45 86 11/48 22.92 14/38 36.84 
HPV 52 161 29/93 31.18 22/68 32.35 
HPV 58 101 9/42 21.43 12/59 20.34 
Footnotes: 
Abbreviation: HPV, human papillomavirus.  
a
 Transient prevalent infection: A prevalent  infection that was detected at only one time point 
b 
Persistent prevalent infection:
 
Persistence of prevalent infection for duration of 6 months or more, that 
cleared at some point during follow-up.  
c
 Transient prevalent recurrent
: 
 Prevalent infections that cleared (2 successive negative DNA results) 
and then recurred during the  follow-up period 
d 
Prevalent persistent recurrent: Persistent prevalent infections that cleared (2 successive negative DNA 
results) and then recurred during the median follow-up time of 48 months. 
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Table 3.1b: Proportion of recurrent infections among men with a prior incident HPV 6, 
11, 16, 18, 31, 33, 45, 52 and 58 infections. 
 
 
HPV types Total incident 
infections 
Transient incident
a
 infections Incident persistent
b
 infections 
Recurrent
c 
/ 
Total incident 
infections 
Proportion
s (%) 
Recurrent
d 
/ 
Total persistent 
infections 
Proportions (%) 
HPV 6 211 15/164 9.15 6/47 12.77 
HPV 11 79 0/60 0.00 5/19 26.32 
HPV 16 249 22/195 11.28 
4/54 
7.41 
HPV 18 121 11/87 12.64 6/34 17.65 
HPV 31 90 6/66 9.09 3/24 12.50 
HPV 33 39 2/33 6.06 
0/6 
0.00 
HPV 45 121 10/99 10.10 3/22 13.64 
HPV 52 204 22/151 14.57 13/53 24.53 
HPV 58 104 14/71 19.72 3/33 9.09 
 
Footnotes: 
Abbreviation: HPV, human papillomavirus.  
a 
Transient incident: An incident infection that was detected at only one time point 
b 
Incident persistent infection: An incident infection that had an observed duration of 6 month or more. 
c
 Transient incident recurrent: incident infections that cleared (2 successive negative results) and then 
recurred during the follow-up period.  
d 
Incident persistent recurrent: Persistent incident infections that cleared (2 successive negative results) 
and then recurred during the median follow-up time of 48 months. 
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Table 3.2a - Factors associated with type specific recurrence of prior prevalent
a
 HPV infections (HPV 6, 16 and 18), with 
sexual behaviors assessed during intervening cleared period
b
  
Behavior variables  HPV 6   HPV 16   HPV 18  
Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 
Smoking           
  Never 124 (79.0) 33 (21.0) 0.9734 138 (78.4) 38 (21.6) 0.6922 49 (80.3) 12 (19.7) 0.9330 
 Former 18 (78.3) 5 (21.7)  14 (70.0) 6 (30.0)  8 (80.0) 2 (20.0)  
 Current 63 (80.8) 15 (19.2)  65 (79.3) 17 (20.7)  26 (83.9) 5 (16.1)  
Alcohol use          
  0-<0.5 drinks/day 84 (84.8) 15 (15.2) 0.1820 85 (75.9) 27 (24.1) 0.7593 22 (75.9) 7 (24.1) 0.4655 
  0.5-<1.5 drinks/day 39 (73.6) 14 (26.4)  44 (77.2) 13 (22.8)  24 (80.0) 6 (20.0)  
  ≥1.5 drinks/day 80 (76.9) 24 (23.1)  85 (80.2) 21 (19.8)  36 (87.8) 5 (12.2)  
Lifetime female 
sexual partners  
         
  0-1 partners 28 (80.0) 7 (20.0) 0.1523 37 (74.0) 13 (26.0) 0.7865 9 (81.8) 2 (18.2) 0.8172 
  2-12 partners 82 (83.7) 16 (16.3)  69 (79.3) 18 (20.7)  33 (84.6) 6 (15.4)  
  >12 partners 82 (72.6) 31 (27.4)  100 (77.5) 29 (22.5)  31 (77.5) 9 (22.5)  
No. of new female 
sexual partners in 
previous 6-12 
months
e 
         
  0 partners 91 (79.8) 23 (20.2) 0.0007 108 (77.1) 32 (22.9) 0.7582 45 (84.9) 8 (15.1) 0.3684 
  1 partners 39 (88.6) 5 (11.4)  31 (75.6) 10 (24.4)  8 (72.7) 3 (27.3)  
  ≥2 partners 26 (56.5) 20 (43.5)  57 (81.4) 13 (18.6)  19 (73.1) 7 (26.9)  
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Footnotes: 
Abbreviations: HPV, human papilloma virus, NA- Not applicable. 
a – Prevalent infections included prevalent infections and prevalent infections that persisted for a duration of 6 months or more.  
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for the type 
specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6 months) and one 
visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).  
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value represents global 
value for overall difference between non-recurrent and recurrent infections.
Table 3.2a (Continued) 
Behavior variables  HPV 6   HPV 16   HPV 18  
Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 
Frequency of sexual 
intercourse with 
female partners in 
last 6-12 months 
         
 0-5  43 (78.2) 12 (21.8) 0.9812 50 (70.4) 21 (29.6) 0.0452 21 (84.0) 4 (16.0) 0.9357 
 6-30 44 (78.6) 12 (21.4)  58 (87.9) 8 (12.1)  15 (78.9) 4 (21.1)  
>30 102 (77.3) 30 (22.7)  101 (76.5) 31 (23.5)  40 (81.6) 9 (18.4)  
Lifetime male sexual 
partners  
         
None 155 (77.1) 46 (22.9) 0.2740 177 (79.0) 47 (21.0) 1.0000 63 (77.8) 18 (22.2) 0.1201 
  ≥1 partners 30 (85.7) 5 (14.3)  21 (77.8) 6 (22.2)  13 (100.0) 0 (0.0)  
No. of new male 
sexual partners in 
previous 6-12 months 
         
  0 partners 160 (77.7) 46 (22.3) 0.8183 181 (78.7) 49 (21.3) 0.7920 68 (79.1) 18 (20.9) 0.1986 
 ≥ 1 partners 24 (80.0) 6 (20.0)  18 (81.8) 4 (18.2)  10 (100.0) 0 (0.0)  
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Table 3.2b - Factors associated with  type specific recurrence of prior prevalent
a
 HPV infections (HPV 6, 16 and 18), with sexual 
behaviors assessed during intervening cleared period
b
  
 
Behavior variables 
 HPV 31  HPV 45  HPV 52 HPV 58 
Non-recurrent Recurrent pc Non-recurrent Recurrent pc Non-recurrent Recurrent pc Non-recurrent Recurrent pc 
 
Smoking  
            
  Never 47 (85.5) 8 (14.5) 1.000 40 (71.4) 16 (28.6) 0.500 57 (62.0) 35 (38.0) 0.109 44 (77.2) 13 (22.8) 0.087 
 Former 2 (100.0) 0 (0.0)   7 (87.5) 1 (12.5)  14 (77.8) 4 (22.2)  3 (50.0) 3 (50.0)  
 Current 20 (83.3) 4 (16.7)  14 (63.6) 8 (36.4)  38 (77.6) 11 (22.4)  33 (86.8) 5 (13.2)  
 
Alcohol use 
            
  0-<0.5 drinks/day 28 (90.3) 3 (9.7) 0.283 28 (80.0) 7 (20.0) 0.313 45 (71.4) 18 (28.6) 0.725 28 (65.1) 15 (34.9)  0.010 
  0.5-<1.5 drinks/day 7 (70.0) 3 (30.0)  10 (62.5) 6 (37.5)  19 (67.9) 9 (32.1)  19 (90.5) 2 (9.5)  
  ≥1.5 drinks/day 31 (83.8) 6 (16.2)  21 (65.6) 11 (34.4)  42 (64.6) 23 (35.4)  33 (89.2) 4 (10.8)  
 
Lifetime female sexual 
partners  
            
  0-1 partners 5 (100.0) 0 (0.0) 0.167 6 (75.0) 2 (25.0) 1.000 14 (82.4) 3 (17.6) 0.206 11 (84.6) 2 (15.4) 1.000 
  2-12 partners 22 (75.9) 7 (24.1)  20 (76.9) 6 (23.1)  37 (72.5) 14 (27.5)  26 (81.3) 6 (18.8)  
  >12 partners 38 (88.4) 5 (11.6)  31 (75.6) 10 (24.4)  52 (62.7) 31 (37.3)  40 (80.0) 10 (20.0)  
 
No. of new female sexual 
partners in previous 6-12 
monthse 
            
  0 partners 30 (88.2) 4 (11.8) 0.032 30 (75.0) 10 (25.0) 0.458 53 (72.6) 20 (27.4) 0.108 45 (83.3) 9 (16.7) 0.149 
  1 partners 8 (61.5) 5 (38.5)  9 (81.8) 2 (18.2)  12 (50.0) 12 (50.0)  15 (78.9) 4 (21.1)  
  ≥2 partners 
 
23 (92.0) 2 (8.0)  15 (62.5) 9 (37.5)  22 (61.1) 14 (38.9)  13 (61.9) 8 (38.1)  
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Footnotes: 
Abbreviations: HPV, human papilloma virus. 
a – Prevalent infections included prevalent infections and prevalent infections that persisted for a duration of 6 months or more.  
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for the type 
specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6 months) and one 
visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).  
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value represents global 
value for overall difference between non-recurrent and recurrent infections.  
Table3.2b (Continued)            
Behavior variables HPV 31 HPV 45 HPV 52 HPV 58 
Non-recurrent Recurrent pc Non-recurrent Recurrent pc Non-recurrent Recurrent pc Non-recurrent Recurrent pc 
Frequency of sexual 
intercourse with female 
partners in last 6-12 
months 
            
 0-5  9 (75.0) 3 (25.0) 0.649 14 (82.4) 3 (17.6) 0.577 25 (71.4) 10 (28.6) 0.103 18 (69.2) 8 (30.8) 0.204 
 6-30 11 (84.6) 2 (15.4)  14 (82.4) 3 (17.6)  28 (82.4) 6 (17.6)  18 (78.3) 5 (21.7)  
>30 45 (86.5) 7 (13.5)  28 (70.0) 12 (30.0)  53 (63.1) 31 (36.9)  43 (86.0) 7 (14.0)  
Lifetime male sexual 
partners  
            
 None 63 (85.1) 11 (14.9) 0.403 47 (70.1) 20 (29.9) 1.000 86 (65.2) 46 (34.8) 0.182 67 (82.7) 14 (17.3) 0.108 
 ≥1 partners 2 (66.7) 1 (33.3)  9 (7.05) 3 (25.0)  14 (82.4) 3 (17.6)  6 (60.0) 4 (40.0)  
No. of new male sexual 
partners in previous 6-
12 monthse 
            
  None 63 (85.1) 11 (14.9) 1.000 49 (69.0) 22 (31.0) 0.429 88 (64.7) 48 (35.3) 0.227 68 (82.9) 14 (17.1) 0.101 
 ≥1 partners 3 (75.0) 1 (25.0)  7 (87.5) 1 (12.5)  11 (84.6) 2 (15.4)  6 (60.0) 4 (40.0)  
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Table 3.3a- Factors associated with type specific recurrence of prior incident
a
 HPV infections (HPV 6, 16 and 
18), with sexual behaviors assessed during intervening cleared period
b
 
 
Behavior variables  HPV 6   HPV 16   HPV 18  
Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 
Smoking           
  Never 133 (90.5) 14 (9.5) 0.7573 160 (92.0) 14 (8.0) 0.0636 69 (86.3) 11 (13.8) 0.8385 
 Former 4 (80.0) 1 (20.0)  11 (91.7) 1 (8.3)  2 (100.0) 0 (0.0)  
 Current 51 (91.1) 5 (8.9)  48 (81.4) 11 (18.6)  31 (83.8) 6 (16.2)  
Alcohol use          
  0-<0.5 drinks/day 84 (94.4) 5 (5.6) 0.1195 90 (90.0) 10 (10.0) 1.0000 44 (86.3) 7 (13.7) 1.0000 
  0.5-<1.5 drinks/day 35 (83.3) 7 (16.7)  48 (88.9) 6 (11.1)  18 (85.7) 3 (14.3)  
  ≥1.5 drinks/day 68 (88.3) 9 (11.7)  81 (89) 10 (11)  41 (85.4) 7 (14.6)  
Lifetime female 
sexual partners  
         
  0-1 partners 25 (92.6) 2 (7.4) 0.8472 30 (88.2) 4 (11.8) 0.3456 5 (100.0) 0 (0.0) 0.6230 
  2-12 partners 68 (90.7) 7 (9.3)  74 (86.0) 12 (14.0)  27 (84.4) 5 (15.6)  
  >12 partners 82 (89.1) 10 (10.9)  100 (92.6) 8 (7.4)  61 (87.1) 9 (12.9)  
No. of new female 
sexual partners in 
previous 6-12 
months
e 
         
  0 partners 104 (92.0) 9 (8.0) 0.5831 117 (88.0) 16 (12.0) 0.4007 39 (84.8) 7 (15.2) 0.7480 
  1 partners 34 (87.2) 5 (12.8)  38 (86.4) 6 (13.6)  14 (93.3) 1 (6.7)  
  ≥2 partners 40 (87.0) 6 (13.0)  60 (93.8) 4 (6.3)  47 (87.0) 7 (13.0)  
 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Footnotes: 
Abbreviations: HPV, human papilloma virus. 
a – Incident infections include incident infections and incident infections that persisted for a duration of 6 months or more.  
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for 
the type specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6 
months) and one visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).  
 
Table 3.3a (Continued) 
Behavior variables HPV 6 HPV 16 HPV 18 
Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 Non-
recurrent 
Recurrent p-value
c
 
Frequency of sexual 
intercourse with 
female partners in 
last 6-12 months 
         
  0-5  40 (93.0) 3 (7.0) 0.7489 51 (89.5) 6 (10.5) 1.0000 15 (83.3) 3 (16.7) 0.1587 
  6-30 45 (88.2) 6 (11.8)  43 (89.6) 5 (10.4)  16 (76.2) 5 (23.8)  
 >30 91 (89.2) 11 (10.8)  114 (89.1) 14 (10.9)  65 (91.5) 6 (8.5)  
Lifetime male sexual 
partners  
         
 None 155 (90.6) 16 (9.4) 0.2851 179 (90.9) 18 (9.1) 1.0000 86 (87.8) 12 (12.2) 0.2276 
 ≥1 partners 20 (83.3) 4 (16.7)  20 (90.9) 2 (9.1)  11 (73.3) 4 (26.7)  
No. of new male 
sexual partners in 
previous 6-12 months 
         
  0 partners 158 (90.8) 16 (9.2) 0.2543 187 (91.2) 18 (8.8) 0.0111 88 (86.3) 14 (13.7) 0.6939 
 ≥ 1 partners 18 (81.8) 4 (18.2)  15 (71.4) 6 (28.6)  11 (78.6) 3 (21.4)  
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c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value 
represents global value for overall difference between non-recurrent and recurrent infections. 
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Table 3.3b- Factors associated with type specific recurrence of prior incident
a
 HPV infections (HPV 31, 45, 52 and 58), with 
sexual behaviors assessed during intervening cleared period
b
 
 
Behavior variables 
 HPV 31  HPV 45  HPV 52  HPV 58 
Non-
recurrent 
Recurrent p-valuec Non-
recurrent 
Recurrent p-
valuec 
Non-
recurrent 
Recurrent p-
valuec 
Non-
recurrent 
Recurrent p-
valuec 
Smoking              
  Never 48 (90.6) 5 (9.4) 1.0000 78 (88.6) 10 (11.4) 1.0000 105 (78.9) 28 (21.1) 0.0488 54 (83.1) 11 (16.9) 0.6941 
 Former 7 (87.5) 1 (12.5)  4 (100.0) 0 (0.0)  8 (72.7) 3 (27.3)  5 (100.0) 0 (0.0)  
 Current 24 (88.9) 3 (11.1)  26 (89.7) 3 (10.3)  53 (93.0) 4 (7.0)  26 (81.3) 6 (18.8)  
Alcohol use             
  0-<0.5 drinks/day 36 (90.0) 4 (10.0) 1.0000 55 (90.2) 6 (9.8) 0.1893 60 (84.5) 11 (15.5) 0.8899 33 (78.6) 9 (21.4) 0.5321 
  0.5-<1.5 drinks/day 20 (90.9) 2 (9.1)  16 (100) 0 (0)  39 (81.3) 9 (18.8)  15 (88.2) 2 (11.8)  
  ≥1.5 drinks/day 24 (88.9) 3 (11.1)  34 (82.9) 7 (17.1)  66 (81.5) 15 (18.5)  39 (86.7) 6 (13.3)  
Lifetime female 
sexual partners  
            
  0-1 partners 14 (87.5) 2 (12.5) 0.6604 17 (94.4) 1 (5.6) 0.6607 17 (70.8) 7 (29.2) 0.1218 10 (90.9) 1 (9.1) 0.9234 
  2-12 partners 23 (95.8) 1 (4.2)  29 (87.9) 4 (12.1)  51 (89.5) 6 (10.5)  23 (85.2) 4 (14.8)  
  >12 partners 38 (90.5) 4 (9.5)  46 (86.8) 7 (13.2)  84 (81.6) 19 (18.4)  45 (83.3) 9 (16.7)  
No. of new female 
sexual partners in 
previous 6-12 
monthse 
            
  0 partners 43 (89.6) 5 (10.4) 0.4763 48 (85.7) 8 (14.3) 0.4800 75 (80.6) 18 (19.4) 0.9020 40 (85.1) 7 (14.9) 0.6666 
  1 partners 11 (100.0) 0 (0.0)  20 (95.2) 1 (4.8)  27 (84.4) 5 (15.6)  13 (76.5) 4 (23.5)  
  ≥2 partners 24 (85.7) 4 (14.3)  30 (90.9) 3 (9.1)  53 (82.8) 11 (17.2)  32 (86.5) 5 (13.5)  
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Footnotes: 
Abbreviations: HPV, human papilloma virus. 
a – Incident infections include incident infections and incident infections that persisted for a duration of 6 months or more.  
b – Intervening cleared period was defined as time period after clearance (two successive negative DNA detections) for the last DNA positive result for 
the type specific incident HPV infection. For recurrent infection it was the visit when recurrence was observed (behavior was inquired for previous 6 
months) and one visit prior to recurrence (incident was cleared during this time and they were susceptible to recurrence).  
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of exact p-values, α = 0.05. p- value 
represents global value for overall difference between non-recurrent and recurrent infection
Table 3.3b (Continued) 
Behavior variables  HPV 31   HPV 45   HPV 52   HPV 58  
Non-
recurrent 
Recurrent p-valuec Non-
recurrent 
Recurrent p-
valuec 
Non-
recurrent 
Recurrent p-
valuec 
Non-
recurrent 
Recurrent p-
valuec 
Frequency of sexual 
intercourse with 
female partners in 
last 6-12 months 
            
 0-5  20 (83.3) 4 (16.7) 0.5339 32 (91.4) 3 (8.6) 0.6701 32 (78.0) 9 (22.0) 0.6089 18 (94.7) 1 (5.3) 0.0886 
 6-30 14 (93.3) 1 (6.7)  20 (90.9) 2 (9.1)  44 (86.3) 7 (13.7)  21 (91.3) 2 (8.7)  
>30 40 (93.0) 3 (7.0)  40 (85.1) 7 (14.9)  78 (82.1) 17 (17.9)  42 (76.4) 13 (23.6)  
Lifetime male 
sexual partners  
            
  None 58 (92.1) 5 (7.9) 0.3575 68 (88.3) 9 (11.7) 0.5014 124 (82.1) 27 (17.9) 0.4253 72 (83.7) 14 (16.3) 1.0000 
  ≥1 partners 13 (81.3) 3 (18.8)  31 (93.9) 2 (6.1)  25 (89.3) 3 (10.7)  7 (77.8) 2 (22.2)  
No. of new male 
sexual partners in 
previous 6-12 
months 
            
  0 partners 59 (92.2) 5 (7.8) 0.3396 73 (89.0) 9 (11.0) 1.0000 129 (82.7) 27 (17.3) 0.2566 71 (83.5) 14 (16.5) 1.0000 
 ≥ 1 partners 13 (81.3) 3 (18.8)  27 (90.0) 3 (10.0)  26 (92.9) 2 (7.1)  9 (81.8) 2 (18.2)  
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Figure 3.3: Proportions of incident and prevalent infection for nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45, 52, and 58) 
according to recurrence status in grouped analyses. 
Footnotes: 
Abbreviation: HPV, human papillomavirus 
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Table 3.4- Demographic characteristics comparing incident infections that recur or do not recur and prevalent infections that recur or do 
not recur for any of the 9 type of HPVs (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among men in the HIM study.  
Demographic variables 
Incident infections Prevalent infections  Prevalent infection for one type and incident 
for another type 
Non-Recurrent 
N (%) 
Recurrent   
N (%)  
p-valuea Non-Recurrent 
N (%) 
Recurrent   
N (%)  
p-valuea Non-Recurrent N 
(%) 
Recurrent   N 
(%)  
p-valuea 
Country          
  United States 144 (84.2) 27 (15.8) 0.1383 139 (74.7) 47 (25.3) 0.7281 30 (51.7) 28 (48.3) 0.3084 
  Brazil 246 (85.4) 42 (14.6)  190 (74.2) 66 (25.8)  83 (56.1) 65 (43.9)  
  Mexico 160 (90.9) 16 (9.1)  154 (77.4) 45 (22.6)  36 (65.5) 19 (34.5)  
Age          
  18-30 255 (87.0) 38 (13.0) 0.7751 243 (78.9) 65 (21.1) 0.0892 90 (58.8) 63 (41.2) 0.8225 
  31-44 215 (87.0) 32 (13.0)  188 (73.2) 69 (26.8)  46 (54.8) 38 (45.2)  
  45-73 80 (84.2) 15 (15.8)  52 (68.4) 24 (31.6)  13 (54.2) 11 (45.8)  
Marital status          
  Single  240 (84.8) 43 (15.2) 0.4867 222 (77.6) 64 (22.4) 0.4352 84 (57.5) 62 (42.5) 0.7864 
  Married/Cohabiting 307 (88.0) 42 (12.0)  209 (73.1) 77 (26.9)  50 (58.1) 36 (41.9)  
Divorced/Separated/Widowed 50 (89.3) 6 (10.7)  49 (75.4) 16 (24.6)  14 (50.0) 14 (50.0)  
Race          
  Whites 234 (82.4) 50 (17.6) 0.0359 227 (73.2) 83 (26.8) 0.4273 72 (56.7) 55 (43.3) 0.9721 
  African-Americans 112 (88.9) 14 (11.1)  70 (77.8) 20 (22.2)  35 (56.5) 27 (43.5)  
  Asians/Pacific  islander 11 (91.7) 1 (8.3)  7 (63.6) 4 (36.4)  2 (66.7) 1 (33.3)  
  Mixed race/Othersb 186 (91.2) 18 (8.8)  172 (78.2) 48 (21.8)  38 (59.4) 26 (40.6)  
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Table 3.4 (Continued) 
Demographic variables Incident infections Prevalent infections  Prevalent infection for one type and incident 
for another type 
Non-Recurrent 
N (%) 
Recurrent   
N (%)  
p-valuea Non-Recurrent 
N (%) 
Recurrent   
N (%)  
p-valuea Non-Recurrent N 
(%) 
Recurrent   N 
(%)  
p-valuea 
          
Education          
  ≤ 12 years 273 (86.4) 43 (13.6) 0.7707 230 (73.7) 82 (26.3) 0.1634 78 (58.6) 55 (41.4) 0.8409 
  13-15 years 141 (85.5) 24 (14.5)  112 (81.8) 25 (18.2)  30 (54.5) 25 (45.5)  
  ≥16 years 135 (88.2) 18 (11.8)  140 (74.1) 49 (25.9)  40 (55.6) 32 (44.4)  
Alcohol use*          
  Non-drinkers 174 (86.6) 27 (13.4) 0.9887 204 (79.7) 52 (20.3) 0.1014 38 (64.4) 21 (35.6) 0.2436 
  <0.5 drinks/day 157 (86.3) 25 (13.7)  114 (71.3) 46 (28.8)  38 (50.0) 38 (50.0)  
  0.5-2 drinks/day 219 (86.9) 33 (13.1)  165 (73.3) 60 (26.7)  73 (57.9) 53 (42.1)  
Cigarette smoking*          
  Never 352 (85.4) 60 (14.6) 0.3288 319 (76.3) 99 (23.7) 0.6832 82 (54.3) 69 (45.7) 0.5879 
  Former smoker 30 (93.8) 2 (6.3)  34 (75.6) 11 (24.4)  8 (57.1) 6 (42.9)  
  Current smoker 168 (88.0) 23 (12.0)  130 (73.0) 48 (27.0)  59 (61.5) 37 (38.5)  
Circumcision          
  No 357 (87.7) 50 (12.3) 0.3357 320 (75.1) 106 (24.9) 0.9233 109 (62.6) 65 (37.4) 0.0111 
  Yes 193 (84.6) 35 (15.4)  163 (75.8) 52 (24.2)  40 (46.0) 47 (54.0)  
Sexual orientation          
  MSW 380 (86.4) 60 (13.6) 0.8233 340 (74.7) 115 (25.3) 0.7534 105 (57.7) 77 (42.3) 0.3327 
  MSM 29 (82.9) 6 (17.1)  20 (76.9) 6 (23.1)  9 (75.0) 3 (25.0)  
  MSWM 70 (85.4) 12 (14.6)  69 (78.4) 19 (21.6)  21 (51.2) 20 (48.8)  
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Table 3.4 (Continued) 
 
 
Demographic variables 
Incident infections Prevalent infections  Prevalent infection for one type and incident 
for another type 
Non-Recurrent 
N (%) 
Recurrent   
N (%)  
p-valuea Non-Recurrent 
N (%) 
Recurrent   
N (%)  
p-valuea Non-Recurrent N 
(%) 
Recurrent   N 
(%)  
p-valuea 
Lifetime female sexual 
partners* 
         
0-1 partners 66 (82.5) 14 (17.5) 0.4199 68 (81.0) 16 (19.0) 0.3773 13 (65.0) 7 (35.0) 0.1971 
2-12 partners 221 (88) 30 (12)  187 (76.0) 59 (24.0)  48 (64.0) 27 (36.0)  
>12 partners 253 (87.2) 37 (12.8)  215 (73.6) 77 (26.4)  82 (52.6) 74 (47.4)  
No. of new female sexual 
partners* 
         
  0 partners 210 (84.0) 40 (16.0) 0.2127 211 (77.0) 63 (23.0) 0.4468 42 (61.8) 26 (38.2) 0.6439 
  1 partners 205 (88.0) 28 (12.0)  150 (73.2) 55 (26.8)  54 (56.8) 41 (43.2)  
  ≥2 partners 131 (89.7) 15 (10.3)  94 (71.8) 37 (28.2)  50 (54.3) 42 (45.7)  
Lifetime male sexual partners*          
  None 466 (88.3) 62 (11.7) 0.0116 392 (74.0) 138 (26.0) 0.3708 119 (56.9) 90 (43.1) 0.9426 
  1-12 34 (87.2) 5 (12.8)  31 (79.5) 8 (20.5)  15 (57.7) 11 (42.3)  
  >12 partners 35 (72.9) 13 (27.1)  30 (83.3) 6 (16.7)  11 (52.4) 10 (47.6)  
No. of new male partners*          
  0 partners 479 (88.4) 63 (11.6) 0.0111 403 (74.6) 137 (25.4) 0.8566 117 (56.8) 89 (43.2) 0.8745 
  1 partners 22 (81.5) 5 (18.5)  30 (73.2) 11 (26.8)  28 (54.9) 23 (45.1)  
  ≥2 partners 36 (73.5) 13 (26.5)  22 (78.6) 6 (21.4)  0 (0.00) 0 (0.00)  
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Footnotes: 
Abbreviations: HPV, human papilloma virus; MSM, men who have sex with men; MSW, men who have sex with women; MSWM, men who have 
sex with women and men 
 
* These variables are based on overall behavior pattern of an individual during the 4 year follow-up time. An individual with most frequent 
behavior (e.g. 0-1 lifetime partners) during the entire follow-up was assigned in that particular category. There will be multiple intervening time 
period (susceptibility period for recurrence) for multiple HPV type infections and analysis based on these different intervals is not possible here.   
 
a - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of p-values, α = 0.05. p- value 
represents global value for overall difference between incident and recurrent infections.  
b - Includes mixed race, American Indians, Alaska natives, Native Hawaiians or other races 
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Table 3.5 – Odds ratio and 95% confidence intervals for recurrent infections by demographic characteristics for 
any of the 9 type of HPVs (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) among men in the HIM study 
 
 Incident infections Prevalent infections Prevalent of one type and incident of another type 
Variables* Strata Crude OR and 
95% CI 
Adjusted ORa and 
95% CI 
Crude OR and 
95% CI 
Adjusted OR and 
95% CI 
Crude OR and 
95% CI 
Adjusted OR and 95% CI 
Alcohol use        
   0-<0.5  1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
   0.5-<1.5  1.03 (0.57 1.84) 1.01 (0.55, 1.91)
a 1.58 (1.00, 2.50) 1.59 (1.01, 2.53)c 1.81 (0.90, 3.63) 1.97 (0.96, 4.06)d 
   ≥1.5  0.97 (0.56, 1.68) 0.90 (0.50, 1.60)
a 1.43 (0.93, 2.18) 1.40 (0.92, 2.15)c 1.31 (0.69, 2.49) 1.22 (0.63, 2.36)d 
Cigarette smoking        
 Never 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
 Former  0.39 (0.09, 1.68) 0.43 (0.10, 1.87)
a 1.04 (0.51, 2.13) 1.06 (0.52, 2.17)c 0.88 (0.30, 2.69) 0.89 (0.29, 2.76)d 
 Current  0.80 (0.48, 1.34) 0.73 (0.42, 1.30)
a 1.19 (0.80, 1.78) 1.21 (0.81, 1.81)c 0.75 (0.44, 1.26) 0.80 (0.46, 1.39)d 
Lifetime female 
sexual partners 
       
 0-1 partners 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
 2-12 partners 0.64 (0.32, 1.28) 0.73 (0.32, 1.66)
a 1.34 (0.72, 2.49) 1.39 (0.74, 2.59)c 1.05 (0.37, 2.93) 1.13 (0.39, 3.25)d 
 >12 partners 0.69 (0.35, 1.35) 
 
0.85 (0.38, 1.92)a 1.52 (0.83, 2.78) 1.50 (0.82, 2.75)c 1.68 (0.64, 4.43) 1.68 (0.63, 4.44)d 
No. of new female 
sexual partners  
       
 0 partners 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
 1 partners 0.72 (0.43, 1.21) 0.91 (0.51, 1.62)
a 1.22 (0.80, 1.86) 1.23 (0.81, 1.87)c 1.23 (0.65, 2.32) 1.14 (0.60, 2.19)d 
 ≥2 partners 0.60 (0.32, 1.13) 0.69 (0.35, 1.35)
a 1.32 (0.82, 2.12) 1.29 (0.79, 2.08)c 1.36 (0.72, 2.57) 1.19 (0.61, 2.33)d 
Frequency of 
intercourse with  
female partners  
       
  0-5  1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
  6-30 0.58 (0.31, 1.09) 0.93 (0.39, 2.23)
a 1.22 (0.73, 2.06) 1.24 (0.74, 2.10)c 1.01 (0.48, 2.14) 1.03 (0.47, 2.21)d 
 >30 0.72 (0.40, 1.31) 1.27 (0.53, 3.04)
a 1.12 (0.67, 1.86) 1.12 (0.68, 1.87)c 1.06 (0.54, 2.10) 0.99 (0.49, 1.98)d 
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Footnotes: HPV- Human papillomavirus, OR-Odds ratio, NE-Not estimable 
* This variables are based on overall behavior pattern of an individual during the 4 year follow-up time. An individual with most frequent 
behavior (e.g. 0-1 lifetime partners) during the entire follow-up was assigned in that particular category. There will be multiple intervening 
time period (susceptibility period for recurrence) for multiple HPV type infections. To address this issue, variables were created based on 
overall behavior pattern instead of based on intervening time interval.   
a- Adjusted for race and lifetime male sexual partners. 
b- Adjusted for race. 
c- Adjusted for country.  
d- Adjusted for country and circumcision status. 
Table 3.5 (Continued) 
 Incident infections Prevalent infections Prevalent of one type and incident of another type 
Variables* Strata Crude OR and 
95% CI 
Adjusted ORa and 
95% CI 
Crude OR and 
95% CI 
Adjusted OR and 
95% CI 
Crude OR and 
95% CI 
Adjusted OR and 95% CI 
 
Lifetime male 
sexual partners 
       
 None 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
 1-12 partners 1.11 (0.42, 2.93) 1.02 (0.38, 2.73)
b 0.73 (0.33, 1.63) 0.71 (0.32, 1.60)c 0.97 (0.43, 2.21) 1.12 (0.48, 2.62)d 
 >12 partners 2.79 (1.40, 5.56)  
 
2.40 (1.19, 4.84)b 0.57 (0.23, 1.39) 0.53 (0.21, 1.32)c 1.20 (0.49, 2.95) 1.26 (0.50, 3.20)d 
No. of new male 
sexual partners  
       
 0 partners 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
 1 partners 1.73 (0.63, 4.73) 1.19 (0.39, 3.61)
b 1.08 (0.53, 2.21) 1.04 (0.50, 2.15)c 1.08 (0.58, 2.00) 1.18 (0.62, 2.26)d 
 ≥2 partners 2.75 (1.38, 5.46) 2.35 (1.16, 4.74)
b 0.80 (0.32, 2.02) 0.76 (0.30, 1.94)c 0.00 (NE) 0.00 (NE) 
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MANUSCRIPT THREE 
 
Introduction: 
          Few studies have reported the natural history of anal HPV infections among men (173-
175). Prevalence of anal HPV was observed to be 47.2 % among men who have sex with men 
(MSM) and 12.2% among men who have sex with women (MSW) for at least one of 37 HPV 
types evaluated (174). Presence of anal HPV among exclusive MSW was an interesting finding 
which raised questions as to how infection at this anatomic site occurs. One of the proposed 
mechanisms is auto-inoculation whereby genital HPV infection is transferred by the heterosexual 
men to the anal epithelium. 
          Only few studies have evaluated concurrent and sequential cervical and anal HPV 
infections among women (176-181). Results of these studies suggested high risk (relative risk as 
high as 14.2) of anal HPV infection among women with previous cervical HPV infections of 
high risk HPV types (177). Acquisition of anal HPV infections among women was also 
associated with having anal sex (177, 178, 181), which is not a likely explanation for 
heterosexual men. Furthermore, receiving anal sex did not entirely explain the high rate of 
sequential cervical to anal HPV infection among women. Thus, auto-inoculation of previous 
cervical infection may also lead to subsequent anal HPV infection observed among women.  
          To date studies examining sequential genital-anal infections have not been conducted 
among men.  In the current study, we assessed type-specific (genotype concordant) sequential 
acquisition of anal HPV infection following a genital HPV infection for nine vaccine HPV types 
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(HPV 6, 11, 16, 18, 31, 33, 45 52 and 58) among MSW participants of the HIM study cohort. We 
also investigated factors associated with incident anal infections following a type-specific genital 
HPV infection.  
Methods: 
Study population 
          The HIM study recruited participants from Tampa, Florida (U.S.), São Paulo (Brazil), and 
Cuernavaca (Mexico) from 2005-2009. Study methodology and recruitment of participants has 
been described in detail previously (182, 183). In brief, 4,123 healthy men from three study sites 
were followed every six months for a median follow-up time of four years. Eligibility criteria for 
the participants were : a) 18–70 years of age; b) residents of one of the study sites; c) no previous 
diagnosis of penile or anal cancers; d) no previous diagnosis of genital warts; e) no symptoms of 
a sexually transmitted infection (STI) and not receiving treatment for an STI; f) not participating 
in an HPV vaccine study; g) no history of HIV or AIDS; h) no history of imprisonment, 
homelessness, or drug treatment during the past six months; and i) willingness to comply with 10 
scheduled visits every six months for four years with no plans to relocate during that time. From 
these study participants, consent was obtained for collection of anal canal exfoliated cell 
samples. Computer-assisted self-interviewing (CASI) was used to administer questionnaires to 
obtain extensive sexual history and demographic characteristics. Signed informed consent was 
obtained from all eligible participants, and approval was obtained from the human subjects 
committees of the University of South Florida (Tampa, FL), Ludwig Institute for Cancer 
Research (São Paulo, Brazil), Centro de Referencia e Treinamento em Doencas Sexualmente 
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Transmissíveis e AIDS (São Paulo, Brazil), and Instituto Nacional de Salud Publica de Mexico 
(Cuernavaca, Mexico). 
External genital and anal HPV DNA samples 
          Genital cell samples from the coronal sulcus/glans penis, penile shaft, and scrotum were 
collected with three prewetted Dacron swabs, which were later combined to form a single genital 
sample (182, 183). After collection of genital specimens, 360° of the anal epithelium was 
swabbed between the anal os and the anal canal dentate line using a separate swab, among 
participants who provided consent for anal specimen collection (173-175). These swabs were 
placed in specimen transport medium and stored at -80°C until analyses. Genital and anal HPV 
DNA was extracted from these samples by the QIAamp DNA Blood Mini Kit (QIAGEN). For 
both genital and anal samples, PCR and HPV genotyping were performed using the Roche 
Linear Array assay to detect 37 HPV genotypes (184). Human β-globin was tested to assess 
specimen adequacy, with an overall β-globin positivity of 98%.  
Statistical analysis 
          All HPV types in the 9-valent vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) were 
assessed for sequential type-specific genital-anal infections. From the HIM study cohort, 81% of 
the men who have sex with women (MSW) consented for collection of anal canal specimens at 
baseline and the first follow-up visit (173). Participants with both genital and anal HPV DNA 
samples at baseline and at least one follow-up visit were included in this analysis. Men who have 
sex with men (MSM), men who have sex with men and women (MSWM), and subjects with anal 
HPV DNA-positive results at baseline were excluded from the genital-anal sequential analyses.  
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          Eligible subjects were assessed for incident anal HPV infection throughout the follow-up 
period at each 6 month clinical visit. Subjects with an incident anal HPV infection were 
categorized into four groups for evaluation of type-specific sequential genital to anal HPV 
infections (Figure 4.1).  These groups were: a) Subjects with genital HPV-positive results at the 
anal HPV-positive visit and genital HPV-negative results in previous visits; b) Subjects with 
genital HPV-negative results at the anal HPV-positive visit and genital HPV-negative  results in 
previous visits; c) Subjects with genital HPV-negative results at the anal HPV-positive visit and 
genital HPV-positive results in previous visits; d) Subjects with genital HPV-positive results at 
the anal HPV-positive visit and with genital HPV-positive results in previous visits. Subjects in 
group a) had concurrent genital and anal infections and were not included in type-specific 
sequential analyses. Subjects without an incident anal HPV infection were also categorized based 
on prior genital HPV infection status constituting the at risk population for incidence rate 
calculations. Characteristics of participants who were susceptible for an incident anal HPV 
infection were compared across prior genital HPV infection status using Chi-square tests and 
Monte Carlo estimation of exact p-values. 
          Anal HPV infection incidence rates and 95% confidence intervals (CI) were calculated 
among men with a prior genital HPV infection and among men with no prior genital HPV 
infection. Incidence rate ratios (IRR) were calculated for each of the nine HPV types comparing 
prior genital and no prior genital infection groups. Grouped analyses were also carried out for 
any of the nine types, low risk HPV types (HPV 6, 11) and high risk HPV types (HPV 16, 18, 
31, 33, 45, 52, and 58). Separate analyses were conducted to assess incidence rates of concurrent 
genital and anal HPV infections (excluded from the sequential analyses). We also examined 
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whether a prior anal infection is associated with incidence of a subsequent genital HPV infection 
by calculating IRR and 95% CI.  
          Risk of sequential detection of anal HPV infections following type-specific genital 
infections was assessed using a Cox proportional hazards model by estimating crude and 
adjusted hazard ratios (HR). Bivariate analyses (adjusting for one co-variable at a time) were 
carried out in HPV individual type analyses. Demographic variables and time varying covariates 
(alcohol use, smoking, sexual behavior variables) were evaluated in adjusted models.  Sample 
size was too small to allow for adjustment of multiple covariates at the same time. Grouped 
analyses for any of the nine types, low-risk types and high-risk HPV types were carried out to 
increase the statistical power to assess risk of sequential genital-anal infections. Demographic 
and sexual behavior variables were evaluated in both backward and forward stepwise models for 
grouped HPV analyses. Final models included variables using the best-fit approach based on the 
lowest Akaike information criterion (AIC) values. 
Results: 
          From the original HIM study cohort of 4,123 men, anal and genital HPV DNA specimens 
for baseline and at least one follow-up visit were available for 2,285 men.  Men with prevalent 
anal HPV infections (n=175) and those who reported either anal or oral sex with a man at any 
time through the study follow-up (n=762) were excluded from the analyses. Subjects excluded 
from the analyses were younger, had a lower education level, and were more likely to be 
MSM/MSWM compared to subjects included in the current analyses. After these exclusions, 
1,348 MSW were eligible for inclusion in the current study. A total of 40 incident anal HPV 
infections were detected during the follow-up period, with 85% of the incident anal infections 
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detected during the first follow-up visit. The median follow-up time in this sub-cohort was 6.8 
months (mean 8.4 months, Inter quartile range: IQR 6.5-7.4).  
          At baseline, 660 men had no prior genital HPV infection and 688 men had a prior genital 
HPV infection with any of the nine HPV types evaluated (Table 4.1). These two groups differed 
significantly by country, with men from Brazil constituting the highest proportion (64.6%) of 
men with a prior genital HPV infection. The two groups also differed by race, with African-
Americans (61.9%) constituting the highest proportion of men with a prior genital infection.  In 
addition, men with prior genital HPV infection reported higher (>2 drinks/day) alcohol use 
(p=0.001), greater number of lifetime female sexual partners (10-49 partners, p <0.001), and 
greater number of new female sexual partners in the previous 6 months (≥2 partners, p=0.001).  
          In individual HPV type analyses, men with HPV 16 genital infections had more than a 4-
fold increased risk of acquiring a subsequent anal HPV 16 infection (Incident rate ratio- IRR= 
4.49, 95% CI 1.14, 18.59) [Table 4.2]. Similarly, risk of acquisition of anal HPV infection was 
significantly higher for HPV 52 (IRR=15.46, 95% CI 2.53, 162.33) and HPV 58 (IRR=22.89, 
95% CI 3.28, 253.09) among men with a prior same type infection at the genitals. In grouped 
analyses, men with prior high risk genital HPV infections had more than a  2-fold increased risk 
of detection of a subsequent anal HPV infection compared to men with no prior genital 
infections ( IRR = 2.61, 95% CI 1.20-6.00, Table 4.2). Overall, men with prior genital HPV 
infections had higher incidence rates of subsequent anal HPV infections. Incident rates for 
concurrent genital and anal HPV infection were low for HPV 18 (IR= 0.18, 95% CI 0.05-0.73) 
and HPV 45 (IR= 0.18, 95% CI 0.4-0.72), and no concurrent infections were observed for other 
HPV types. In contrast, prior anal infections were not associated with risk of subsequent genital 
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infections (IRR 1.18; 95% CI, 0.64-2.01 for high risk type HPVs and IRR 0.72; 95% CI, 0.09-
2.65 for HPV 16). 
          In Cox proportional hazard analyses, statistically significant HRs for anal HPV infection 
after a genital infection were observed for HPV 16 (HR=4.63, 95% CI 1.41-15.23), HPV 52 
(HR=15.78, 95% CI 3.04-81.92) and HPV 58 (HR=19.60, 95% CI 3.56-107.79) [Table 4.3]. 
These HRs remained statistically significant even after adjusting for demographic and time 
varying covariates one at a time (Table 4.3 and Appendix Table 4.1, 4.1b). Similar to the IRR 
analyses, a higher but non-significant HR was observed for HPV 6 (HR=4.6, 95% CI 0.93-22.84) 
for detection of anal HPV infection after a genital infection. In grouped HPV analyses, 
significantly higher adjusted hazard ratios (aHR) were observed for infection with any of the 
nine HPV types (aHR= 2.8, 95% CI1.32-5.99), low risk HPV types (aHR=5.89, 95% CI1.29, 
27.01), and high risk HPV types (aHR=2.65, 95% CI 1.26, 5.55). Infection with any of the nine 
HPV types, low risk HPV types and high risk HPV types were also evaluated by adjusting one 
variable at a time with HRs remaining significant after adjustment for demographic and time 
varying covariates (Table 4.3 and Appendix Table 4.1a, 4.1b).  
Discussion:  
          This is the first study to report sequential type-specific genital and anal HPV infections 
among MSW for the HPV types included in the 9-valent vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 
52, and 58).  Overall, having a prior genital HPV infection increased the risk of a subsequent anal 
infection of the same HPV type, and this association was unaffected by adjusting for sexual 
behavior. Men with a prior genital HPV 16 infection had more than a four-fold increased risk of 
anal HPV 16 infection compared to men with no prior genital HPV 16 infections. Significantly 
higher risk of sequential anal infection after a genital infection were observed in combined 
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analyses for high risk HPV types, low risk HPV types, and any of the nine HPV types targeted 
by vaccine.  
          In previous publications, anal HPV infections were detected among MSW with a 
prevalence of 12.2% for any HPV type and 2.2% for HPV 16 (174). It is not clear how MSW 
acquire these infections. Our study provides the first evidence of auto-inoculation of genital 
infections as a possible mechanism. Among women, only two studies have assessed sequential 
acquisition of type-specific anal HPV infection from a prior cervical infection. A study in the 
Hawaii HPV cohort found a high risk for sequential cervical to anal HPV infection with an aHR 
of 17.33 (95% CI 10.22–29.39) for any type and an aHR of 13.25 (95% CI 3.43–51.22) for HPV 
types 16 and 18 (176). Another study from the same cohort also found a high risk for sequential 
acquisition of anal infections after cervical infection, with a relative risk (RR) of 20.5 (95% CI: 
16.3-25.7) for any HPV type and a RR of 14.2 (9.86-20.5) for high risk HPV types (177). Other 
studies have also indicated associations between anal and cervical HPV infections, although they 
did not conduct sequential analyses. A study found high concurrence rate of anal and cervical 
HPV infections with an adjusted odds ratio (aOR) of 3.3 (95% CI, 2.5-4.4) (178). In a study 
among women in American Samoa, authors’ found that women with anal HPV infections were 
more likely to have a history of prior cervical infections (aOR = 3.32, 95% CI 1.10–10.00) (179). 
Another study found that anal HPV infections were associated with cervical HPV infection with 
a relative risk (RR) = 1.3 (95% CI, 1.1–1.4) (180). A concordance rate of 20% for anal HPV 
infections among women with pre-existing cervical HPV infections was observed in another 
study (181). 
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          In this study, risk of sequential acquisition of anal HPV infections was unaffected by 
sexual behavior and other demographic characteristics. Our analyses included exclusively MSW 
subjects and excluded any subjects who reported either oral or anal sex with men throughout the 
follow-up period. As number of female sexual partners and frequency of sexual intercourse with 
women did not explain presence of anal HPV infections, a likely explanation of these infections 
is auto-inoculation through prior genital infections. Auto-inoculation from genital infections may 
occur through contact of the hand, toilet paper, undergarments, towel, or other objects. Digital 
contact through female sexual partners is also a possibility, but we did not have information 
available to assess such transmission. Absence of other explanatory factors and significantly high 
risk of sequential infections observed in our analyses indicate that auto-inoculation is a likely 
explanation.  
          To the best of our knowledge, no other study has assessed the risk of type-specific 
sequential genital-anal infections among heterosexual men. Strengths of the current study are 
large sample size, multinational nature of the cohort, and standard HPV DNA genotyping 
methods (190-194). Apart from these strengths, the following limitations may have affected our 
results. Despite these strengths, there are limitations that need to be considered when interpreting 
study results.  We did not have information regarding HPV infections prior to the study start; 
therefore, participants may have had genital HPV infections prior to enrollment that 
subsequently cleared.  This may have led to misclassification of participants with respect to  their 
classification of their prior genital infection status.  It is also possible that participants acquired 
anal HPV infections prior to the study start. These infections may have been latent and later 
detected and classified as incident anal infections during the follow-up. Similar to genital HPV 
infections, it is possible that anal HPV infections may be retained in a latent state in basal 
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epithelial stem cell pool (185-189).  However, re-activation of a latent infection is less likely in 
immune competent HIM study participants, and the detection of very low viral load of a latent 
infection is not possible with current HPV DNA detection methods (186-188). Future studies are 
needed to assess the role of latent HPV infections particularly in immune-competent individuals. 
          Although 2,285 subjects provided anal specimens at baseline, fewer specimens were 
available after the fourth visit. Subjects were either lost to follow-up or excluded due to reporting 
of anal/oral sex with men during follow-up visits. Therefore, we carried out grouped analyses to 
increase power to assess sequential genital-anal infection for any of the nine types, high-risk 
types, and low-risk HPV types. Eligible participants may not have reported having male sexual 
partners due to social desirability. Use of computer assisted techniques for recording sexual 
behavior history should have minimized the effect of such bias. Misclassification of genital and 
anal HPV infection status is also possible, especially for infections with low viral load and long 
time periods between initial infection and assessment of HPV DNA. Given the robust methods 
used for HPV DNA detection in our study, effect of such misclassification should be minimal 
(190-194). Furthermore, subjects included in the analyses did not differ from excluded subjects 
for sexual behavior variables.   
          In conclusion, men with prior genital HPV infections are at higher risk of acquiring anal 
infections with the same type, with a more than four-fold increased risk for HPV 16. Auto-
inoculation of genital HPV infection along with other unknown factors may explain the presence 
of anal HPV among MSW. Future studies are needed to assess the role of auto-inoculation and 
explore other factors associated with high rates of anal HPV infection following a genital 
infection among MSW. These findings also suggest that the prevention of genital HPV infection 
94 
 
through vaccination and other methods may help curtail anal HPV infection among heterosexual 
men. 
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Figure 4.1: Study population for assessment of sequential genital and anal HPV infections among participants of the HIM 
study 
MSM and 
MSWM* subjects 
(N= 762) 
Men with prevalent 
anal HPV infections 
(N= 175) 
Eligible subjects: MSW without a 
prevalent anal HPV infection 
(N= 1,348) 
Concurrent 
acquisition 
(excluded from 
sequential 
analysis) 
Genital HPV (-) in 
previous visits and 
Genital HPV (+) at 
Anal HPV (+) visit
a
 
Genital HPV (-) in 
previous visits and 
Genital HPV (-) at 
Anal HPV (+) visit
b
 
Genital HPV (+) in 
previous visits and 
Genital HPV   (-) at 
Anal HPV (+) visit
c
  
Genital HPV (+) in 
previous visits and 
Genital HPV (+) at 
Anal HPV (+) visit
d
 
The HIM study Participants 
(N= 4,123) 
Anal HPV testing 
(N= 2,285) 
Men with no prior genital HPV infection** 
(N= 660) 
 
Men with prior genital HPV infections** 
(N= 688) 
 
a) b) c) d) 
Excluded 
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Footnotes: HPV- Human Papillomavirus. Each genital and anal HPV infection assessed is type-specific (genotype concordant). (+) means HPV 
DNA positive result and (-) means HPV DNA negative result. 
*MSM - men who have sex with men, MSWM - Men who have sex with men and women 
** No prior genital and prior genital infection status are based on the sequential acquisition of anal HPV infections as indicated by the sub-boxes 
following each of these groups.  
a- Genital and anal infections occurred at the same visit, so cannot assess sequential risk. Number of men positive according to each type: HPV 6- 
4, HPV 11- 5, HPV 16- 10, HPV 18 – 3, HPV 31- 1,   HPV 33- 1, HPV 45- 8, HPV 52- 4, HPV 58- 2 
b- Number of men positive according to each type: HPV 6- 3, HPV 11- 0, HPV 16- 5, HPV 18 – 4, HPV 31- 0,   HPV 33- 1, HPV 45- 3, HPV 52- 
2, HPV 58- 2 
c- Number of men positive according to each type: HPV 6- 1, HPV 11- 0, HPV 16- 3, HPV 18 – 0, HPV 31- 1,   HPV 33- 0, HPV 45- 0, HPV 52- 
2, HPV 58- 2 
d- Previous genital HPV positive visit was used for to assess risk of subsequent anal infections. Number of men positive according to each type: 
HPV 6- 2, HPV 11- 1, HPV 16- 3, HPV 18 – 0, HPV 31- 0,   HPV 33- 0, HPV 45- 0, HPV 52- 3, HPV 58- 2 
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Table 4.1:  Demographic characteristics of MSW (men who have sex with women) according to prior genital HPV infection 
with any of the nine type HPVs (6, 11, 16, 18, 31, 33, 45, 52, and 58), among subjects anal HPV negative at baseline in the HIM 
study 
 
 Entire 
Population 
(N=1,348) 
No prior genital 
infection
a
 
(N=660) 
Prior genital 
infection
b
 
(N=688) 
P-value
c
 
Country of Residence     
United States 510 (37.8) 265 (52.0) 245 (48.0) <.0001 
Brazil 325 (24.1) 115 (35.4) 210 (64.6)  
Mexico 513 (38.1) 280 (54.6) 233 (45.4)  
 
Age, years 
18-30 641 (47.6) 313 (48.8) 328 (51.2) 0.8082 
31-44 501 (37.2) 242 (48.3) 259 (51.7)  
45-73 206 (15.3) 105 (51.0) 101 (49.0)  
 
Marital Status 
Single or never married 543 (40.4) 256 (47.1) 287 (52.9) 0.0710 
Married/Cohabitating 670 (49.9) 347 (51.8) 323 (48.2)  
Divorced/Separated/Widowed 130 (9.7) 55 (42.3) 75 (57.7)  
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Table 4.1 (Continued) 
 Entire 
Population 
(N=1,348) 
No prior genital 
infection
a
 
(N=660) 
Prior genital 
infection
b
 
(N=688) 
P-value
c
 
Race     
White 589 (44.1) 273 (46.3) 316 (53.7) <.0001 
African Americans 160 (12.0) 61 (38.1) 99 (61.9)  
Asian/Pacific Islander 33 (2.5) 26 (78.8) 7 (21.2)  
Mixed race/Others
d
 555 (41.5) 296 (53.3) 259 (46.7)  
 
Education, years 
<= 12 578 (43.0) 285 (49.3) 293 (50.7) 0.9708 
13-15 363 (27.0) 178 (49.0) 185 (51.0)  
>= 16 404 (30.0) 196 (48.5) 208 (51.5)  
 
Alcohol use 
No alcohol 276 (20.9) 144 (52.2) 132 (47.8) 0.0010 
<0.5 drinks/day 484 (36.6) 258 (53.3) 226 (46.7)  
0.5-2 drinks/day 347 (26.2) 165 (47.6) 182 (52.4)  
> 2 drinks/day 216 (16.3) 83 (38.4) 133 (61.6)  
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Table 4.1 (Continued) 
 Entire 
Population 
(N=1,348) 
No prior genital 
infection
a
 
(N=660) 
Prior genital 
infection
b
 
(N=688) 
P-value
c
 
Smoking status     
Never 776 (57.6) 376 (48.5) 400 (51.5) 0.3432 
Former 275 (20.4) 145 (52.7) 130 (47.3)  
Current 296 (22.0) 139 (47.0) 157 (53.0)  
 
Circumcision 
No 771 (57.2) 377 (48.9) 394 (51.1) 1.0000 
Yes 577 (42.8) 283 (49.0) 294 (51.0)  
 
Lifetime female sexual partners 
0-1 114 (8.5) 79 (69.3) 35 (30.7) <.0001 
2-9 662 (49.1) 358 (54.1) 304 (45.9)  
10-49 484 (35.9) 183 (37.8) 301 (62.2)  
>= 50 88 (6.5) 40 (45.5) 48 (54.5)  
New female sexual partners  
in previous 6 months 
None 843 (65.0) 440 (52.2) 403 (47.8) 0.0011 
1 340 (26.2) 146 (42.9) 194 (57.1)  
>= 2 114 (8.8) 44 (38.6) 70 (61.4)  
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Footnotes: 
Abbreviation: HPV, human papillomavirus; MSW, men who have sex with women. 
a - No prior genital infection group includes participants who are susceptible to acquire anal incident infection and do not have prior type 
specific genital HPV infection. 
b – With prior genital infection group includes participants who are susceptible to acquire anal incident infection and have a prior type 
specific genital HPV infection. 
c - p-values for categorical variables were calculated using the chi-square test with Monte Carlo estimation of p-values, α = 0.05,  
d - Includes mixed race, American Indians, Alaska natives, Native Hawaiians or other races 
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Table 4.2: Incidence rate of anal human papillomavirus (HPV) infection, by prior genital HPV infection status among MSW 
(men who have sex with women) in the HIM Study 
No prior genital HPV infection Prior genital HPV infection 
HPV 
types 
Subjects 
at risk 
Incident 
infections 
Person- 
months 
Incidence per 
1000 person- 
months 
(95% CI) 
Subjects 
at risk 
Incident  
infections 
Person- 
month 
Incidence per 
1000 person- 
months 
(95% CI) 
Incidence 
rate ratio 
(95% CI) 
Any 
type* 
660 12 5704.0 2.10 (0.12, 3.70) 
688 25
a
 5817.8 4.29 (2.90, 6.36) 2.04 (0.99, 4.46) 
Low risk 
types** 
1086 3 9542.3 0.31 (0.10, 0.98) 
262 4 2288.8 1.75 (0.65, 4.66) 5.56 (0.94, 37.95) 
High risk 
types*** 
772 11 6695.1 1.64 (0.91, 2.97) 
576 21
a
 4895.0 4.30 (2.80, 6.58) 2.61 (1.20, 6.00) 
          
HPV 6 1104 3 9554.1 0.31 (0.10, 0.97) 224 3 1967.3 1.52 (0.49, 4.73) 4.86 (0.65, 36.26) 
HPV 11 1299 0 11441.5 0.00 (NE) 47 1 437.7 2.28 (0.32,16.22) NE 
HPV 16 1036 5 9034.6 0.55 (0.23, 1.33) 286 6 2415.7 2.48 (1.11, 5.53) 4.49 (1.14, 18.59) 
HPV 18 1249 4 10902.3 0.37 (0.14, 0.98) 95 0 856.2 0.00 (NE) NE 
HPV 31 1259 0 11164.6 0.00 (NE) 84 1 707.2 1.41 (0.20, 1.00) NE 
HPV 33 1325 1 11691.3 0.09 (0.01, 0.61) 21 0 180.6 0.00 (NE) NE 
HPV 45 1261 3 11102 0.27 (0.09, 0.84) 81 0 682.1 0.00 (NE) NE 
HPV 52 1169 2 10142.3 0.20 (0.24, 1.17) 176 5 1640.3 3.05 (1.10, 6.33) 15.46 (2.53, 162.33) 
HPV 58 1241 2 10875.8 0.18 (0.08, 0.76) 104 4 950.1 4.21 (1.40, 9.95) 22.89 (3.28, 253.09) 
Footnotes: Prior genital HPV infection with the same HPV genotype. All the participants were MSWs (men who have sex with women) and never 
reported having anal or oral sex with men during the 4 year follow-up time. 
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58) 
** Low risk types include HPV 6 and 11 
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 58 
NE=Not estimable. Incidence rate ratio and 95% confidence intervals were calculated using a Poisson model with log link function;
 
Included in the 
9-valent HPV vaccine. 
a- Combining different HPV types for analyses resulted in higher number of incident anal infections among men with prior genital infection with 
any of the nine types and the high risk HPV types. 
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Footnotes: 
Reference group consists of men without a prior genital HPV infection of the same genotype 
 
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58) 
** Low risk types include HPV6 and 11 
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 5 
 
Table 4.3: Risk of sequential acquisition of anal human papillomavirus (HPV) infection following a genital 
HPV infection among MSW (men who have sex with women)  in the HIM Study 
 
HPV types 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Adjustedd 
HR (95% CI) 
Adjustede 
HR (95% CI) 
Adjustedf 
HR (95% CI) 
Adjustedg 
HR (95% CI) 
Any type* 2.19 (1.10, 4.39) 2.81 (1.32, 5.99)a 2.28 (1.10, 4.72) 2.53 (1.21, 5.29) 5.14 (1.40, 18.82) 5.14 (1.40, 18.82) 
Low risk 
types** 
5.41 (1.21, 24.16) 5.89 (1.29, 27.01)b 5.16 (1.15, 23.17) 7.80 (1.41, 43.16) NE NE 
High risk 
types*** 
2.89 (1.38, 6.02) 2.65 (1.26, 5.55)c 
3.13 (1.43, 6.83) 
3.34 (1.53, 7.28) 6.95 (1.91, 25.27) 6.95 (1.91, 25.27) 
       
6 4.61 (0.93, 22.84) NE 4.66 (0.92, 23.56) 6.19 (1.03, 37.25) NE 5.65 (1.13, 28.24) 
11 NE NE NE NE NE NE 
16 4.63 (1.41, 15.23) NE 4.46 (1.34, 14.85) 6.44 (1.91, 21.66) 6.50 (1.06, 39.69) 5.22 (1.55, 17.57) 
18 NE NE NE NE NE NE 
31 NE NE NE NE NE NE 
   33 NE NE NE NE NE NE 
45 NE NE NE NE NE NE 
52 15.78 (3.04, 81.92) NE 23.35 (2.57, 211.94) 14.52 (2.77, 76.03) 17.95 (1.33, 242.47) NE 
58 19.60 (3.56, 107.79) NE 23.50 (4.19, 131.84) 23.56 (3.72, 149.07) 40.54 (4.51, 364.28) 35.70 (5.11, 249.28) 
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a- Adjusted for marital status and frequency of sexual intercourse with female partners as a time varying covariate based on  
      best fit model 
b- Adjusted for country based on best fit model 
c- Adjusted for marital status based on best fit model 
d- Adjusted for alcohol use as a time varying covariate 
e- Adjusted for lifetime female sexual partners as a time varying covariate 
f- Adjusted for number of new female partners in past 6-12 months as a time varying covariate 
g- Adjusted for frequency of sexual intercourse with female partners as a time varying covariate 
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CONCLUSION AND RECOMMENDATIONS 
 
         HPV infections among men are associated with HPV-related diseases in both men and 
women. Early studies of HPV focused on infection among women, and it is just recently that we 
have begun to study HPV infection among men. We have learned that men’s response to HPV 
infection is different from that of women, making it important to study and understand the 
natural history of HPV infection among men. Results discussed here provide important 
information in regards to incidence, persistence, and recurrence of anogenital α- mucosal HPV 
types 6, 11, 16, 18, 31, 33, 45, 52 and 58.  
          Results from section 3.3 suggest that men with anti-HPV antibodies largely remain 
susceptible to genital HPV infections as these antibodies do not provide protection against 
subsequent infections with HPV types 6, 11 and 16. There was an indication of a protective 
effect for persistent HPV 18 infections. Various factors associated with measurement/assessment 
of serum antibody level can affect anti-HPV antibody levels. With current suboptimal HPV 
vaccine coverage among both men and women in U.S., it is essential to promote HPV 
vaccination and other preventive measures to target HPV-associated diseases.  
          Section 4.3 results provide the first description of the recurrence of genital HPV infections 
among men.  We observed high rates of recurrence for both prevalent (up to 31%) and incident 
(up to 20%) HPV infections.  Recurrence of genital HPV infections was associated with high risk 
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sexual behaviors, such as greater numbers of new sexual partners and lifetime sexual partners. 
Analysis of recurrent infections also presents various challenges, including obtaining information 
about all prior genital infections, issues associated with differentiating infections from steady 
partners and new partners, and the possibility of HPV latency. Future studies are needed to 
assess recurrence of HPV infections and explore their role in etiology of HPV-associated 
diseases.  
          Results from section 5.3 are also the first to report sequential acquisition of anal HPV 
infection following a type-specific genital infection among MSW. Men with prior genital HPV 
16 infections had a more than four-fold increased risk of acquiring subsequent anal HPV 16 
infections. Higher hazard ratios were also observed for any of the nine HPV types, high risk 
HPV types, and low risk HPV types. In the absence of other explanatory factors, the high risk of 
sequential genital-anal infection suggests that auto-inoculation of genital infection is a likely 
mechanism for anal HPV acquisition among MSW. Future studies are needed to further explore 
this association. 
          These results provide essential information about the natural history of HPV infection 
among men. From a public health perspective, it is important to understand the natural history of 
HPV and use this information to control HPV infections and subsequent diseases in both men 
and women.  
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APPENDIX 
Appendix A:Table 2.1- Crude and adjusted hazard ratios (HR) according to sero-status for HPV 6, 11, 16 and 18 
infections among men in the HIM study 
 
Incident 
infection 
Crude HR and 
95% CI 
Adjusted HR 
and 95% CI
a
 
Adjusted HR 
and 95% CI
b
 
Adjusted HR 
and 95% CI
c
 
Adjusted HR 
and 95% CI
d
 
Adjusted HR 
and 95% CI
e
 
Adjusted HR 
and 95% CI
f
 
        
 
 
       
HPV 6        
Sero - 1.00  1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 1.08 (0.74, 1.56) 1.11 (0.76, 1.62) 1.05 (0.71, 1.55) 1.00 (0.63, 1.57) 1.00 (0.69, 1.46) 0.95 (0.64, 1.40) 0.93 (0.62, 1.39) 
        
HPV 11        
Sero - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 0.92 (0.55, 1.54) 0.83 (0.49,1.41) 0.88 (0.51, 1.51) 0.78 (0.42, 1.47) 0.83 (0.49,1.39) 0.83 (0.49,1.40) 0.74 (0.43, 1.30) 
        
HPV 16        
Sero - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 1.40 (1.08, 1.81) 1.36(1.05 1.77) 1.39 (1.07 1.82) 1.38 (1.03, 1.85) 1.32 (1.02, 1.71) 1.34 (1.03, 1.76) 1.31 (0.997, 
1.73) 
        
HPV 18        
Sero - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 0.92 (0.59, 1.43) 0.91 (0.58, 1.43) 1.01 (0.65, 1.57) 0.95 (0.57, 1.59) 0.84 (0.54, 1.31) 0.80 (0.50, 1.23) 0.82 (0.52, 1.30) 
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Footnotes: HPV- Human Papillomavirus, HR- Hazard ratios 
a - Adjusted for non-sexual behavior covariates  
b - Adjusted for lifetime female sexual partners (time varying) 
c - Adjusted for new female partners in past 6-12 months (time varying) 
d - Adjusted for ever having male oral/anal sexual partners (time varying). 
e - Adjusted for lifetime male sexual partners (time varying) 
f - Adjusted for new male partners in past 6-12 months (time varying)
Appendix A:Table 2.1 (Continued) 
6 month 
persistent 
infection 
Crude HR and 
95% CI 
Adjusted HR 
and 95% CI
a
 
Adjusted HR 
and 95% CI
b
 
Adjusted HR 
and 95% CI
c
 
Adjusted HR 
and 95% CI
d
 
Adjusted HR 
and 95% CI
e
 
Adjusted HR 
and 95% CI
f
 
 
HPV 6 
       
Sero - 1.00  1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 0.80 (0.37,  1.73) 0.93 (0.43, 2.00) 0.93 (0.43, 2.01) 0.84 (0.34, 2.07) 0.81 (0.37, 1.75) 0.87 (0.40, 1.89) 0.86 (0.39, 1.87) 
        
HPV 11        
Sero - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 0.32 (0.08, 1.34) 0.36 (0.09, 1.48) 0.17 (0.02, 1.21) 0.20 (0.03, 1.50) 0.29 (0.07, 1.20) 0.32 (0.07, 1.35) 0.38 (0.09, 1.60) 
        
HPV 16        
Sero - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 1.26 (0.79, 2.01) 1.27(0.79, 2.03) 1.24 (0.77, 1.99) 1.35 (0.81, 2.27) 1.21 (0.75, 1.93) 1.27 (0.78, 2.06) 1.24 (0.76, 2.04)
 
 
        
HPV 18        
Sero - 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Sero + 
 
 
0.22 (0.06, 0.91) 0.24 (0.06, 
0.997) 
0.24 (0.06, 1.01) 0.17 (0.02, 1.26) 0.20 (0.05, 0.82) 0.23 (0.06, 0.93) 0.22 (0.05, 0.92) 
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Appendix B: Table 2.2 - Crude and adjusted hazard ratios (HR) stratified by sexual orientation for incident 
HPV 6 and 11 infections among HIM Study participants 
   
  HPV 6 HPV 11 
  
Number 
at risk Events Crude HR Adjusted HR 
Number 
at risk Events Crude HR Adjusted HR 
Incident 
infections 
 
  
 
  
 
  
 
  
MSW 
 
  
 
  
 
  
 
  
Seronegative 2345 235 1.0 1.0 2374 75 1.0 1.0 
Seropositive 170 14 0.86 (0.50, 1.47)  1.06 (0.58, 1.97 )
a
 326 6 0.57 (0.25, 1.32)  0.75 (0.32, 1.75 )
b
 
  
 
  
 
  
 
  
 
  
MSWM 
 
  
 
  
 
  
 
  
Seronegative 292 40 1.0 1.0 292 20 1.0 1.0 
Seropositive 56 12 1.66 (0.87, 3.16) 1.10 (0.50, 2.46)
c
 96 4 0.62 (0.21, 1.82) 0.60 (0.20, 1.83)
d
 
  
 
  
 
  
 
  
 
  
MSM 
 
  
 
  
 
  
 
  
Seronegative 77 14 1.0 1.0 77 7 1.0 1.0 
Seropositive 22 3 0.81 (0.23, 2.80) 0.50 (0.11, 2.32)
e
 30 3 1.31 (0.33, 5.26) 1.99 (0.44, 8.99)
e
 
  
 
  
 
  
 
  
 
  
Six month 
persistent 
infections 
 
  
 
  
 
  
 
  
MSW 
 
  
 
  
 
  
 
  
Seronegative 2345 235 1.0 1.0 2374 75 1.0 1.0 
Seropositive 170 14 1.13 (0.49, 2.60) 1.41 (0.56, 3.55)
f
 326 6 0.30 (0.04, 2.20) 0.35 (0.05, 2.57)
g
 
  
 
  
 
  
 
  
 
  
MSWM 
 
  
 
  
 
  
 
  
Seronegative 292 40 1.0 1.0 292 20 1.0 1.0 
Seropositive 56 12 0.47 (0.06, 3.59) 0.53 (0.07, 4.15)
h
 96 4 NE NE 
  
 
  
 
  
 
  
 
  
MSM 
 
  
 
  
 
  
 
  
Seronegative 77 14 1.0 1.0 77 7 1.0 1.0 
Seropositive 22 3 NE NE 30 3 1.33 (0.12, 14.72) 1.16 (0.11, 12.83)
i
 
      Footnotes: 
HPV- Human Papillomavirus, HR- Hazard ratios, MSW- Men who have sex with women, MSWM- Men who have sex 
with women and men, MSM- Men who have sex with men 
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a- Adjusted for marital status, alcohol use, lifetime female partners (time varying) and new female partners in past 6-12 
months(time varying) 
b-Adjusted for country, marital status,  and new female partners in past 6-12 months(time varying) 
 c- Adjusted for race, new female partners in past 6-12 months(time varying) and new male partners in past 6-12 
months(time varying) 
d- Adjusted for marital status, lifetime female partners (time varying) and new male partners in past 6-12 months(time 
varying) 
e - Adjusted for new male partners in past 6-12 months(time varying) 
      f- Adjusted for alcohol use, new female partners in past 6-12 months (time varying) and frequency of sexual 
intercourse with female partners in past 6-12 months. 
g-Adjusted for smoking, and new female partners in past 6-12 months(time varying) 
h- Adjusted for country, i- Adjusted for age 
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Appendix C: Table 2.3 – Incident rate ratios comparing high (top 33.3%) seropositive to seronegative and low 
seropositive (lower 66.7%) to seronegative individuals for incident and six month persistent infection for HPV6, 
11, 16 and 18.  
 
 High seropositive (Top 33.3%)  Seronegative  
  No. At 
risk 
Person-
years 
Incidence rate 
per 100 person-
years 
No. At 
risk 
Person-
years 
Incidence 
rate per 100 
person-years 
Incidence rate 
ratio and 95% CI 
Incident infections     
HPV 6 12 89 291.8 4.11 319 3105 10898.7 2.93 1.41 (0.72, 2.49) 
HPV 11 6 176 628.7 0.95 111 3132 11404.3 0.97 0.98 (0.35, 2.20) 
HPV 16 22 137 450.8 4.88 362 2912 10177.2 3.56 1.37 (0.85, 2.11) 
HPV 18 7 126 439.6 1.59 200 3202 11578.6 1.73 0.92 (0.37, 1.93) 
6-Month persistent infections      
HPV 6 2 89 297.7 0.67 100 3105 11025.7 0.91 0.74 (0.09, 2.75) 
HPV 11 0 176 634.4 0.00 37 3132 11451 0.32 0.00 (NE) 
HPV 16 5 137 460.2 1.09 120 2912 10310.2 1.16 0.93 (0.30, 2.24) 
HPV 18 1 126 442.2 0.23 74 3202 11642.9 0.64 0.36 (0.01, 2.05) 
 Low seropositive (Lower 66.7%)  Seronegative  
  No. At 
risk 
Person-
years 
Incidence rate 
per 100 person-
years 
No. At 
risk 
Person-
years 
Incidence 
rate per 100 
person-years 
Incidence rate 
ratio and 95% CI 
Incident infections     
HPV 6 18 194 663.75 2.71 319 3105 10898.7 2.93 0.93 (0.54, 1.49) 
HPV 11 11 337 1260.1 0.87 111 3132 11404.3 0.97 0.90 (0.44, 1.67) 
HPV 16 48 283 964.8 4.98 362 2912 10177.2 3.56 1.40 (1.01, 1.89) 
HPV 18 15 265 962.6 1.56 200 3202 11578.6 1.73 0.90 (0.49, 1.52) 
6-Month persistent infections      
HPV 6 5 194 669.1 0.75 100 3105 11025.7 0.91 0.82 (0.26, 1.99) 
HPV 11 2 337 1265.6 0.16 37 3132 11451 0.32 0.49 (0.06, 1.90) 
HPV 16 16 283 981.1 1.63 120 2912 10310.2 1.16 1.40 (0.78, 2.37) 
HPV 18 1 265 968.7 0.10 74 3202 11642.9 0.64 0.16 (0.004, 0.93) 
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Footnotes: HPV- Human Papillomavirus 
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Footnotes: 
Reference group consists of men without a prior genital HPV infection of the same genotype 
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58) 
** Low risk types include HPV6 and 11 
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 5 
 
a
Adjusted for country 
b
Adjusted for age  
c
Adjusted for marital status 
Appendix D: Table 4.1a: Risk of sequential acquisition of anal human papillomavirus (HPV) infection following a 
genital HPV infection 
 
  Country Age Marital status Race 
HPV types 
Crude 
HR (95% CI) 
Adjusted
a
 
HR (95% CI) 
Adjusted
b
 
HR (95% CI) 
Adjusted
c 
HR (95% CI) 
Adjusted
d 
HR (95% CI) 
Any type
*
 2.19 (1.10, 4.39) 2.20 (1.09, 4.45) 2.25 (1.13, 4.51) 2.01 (1.00, 4.05) 2.24 (1.11, 4.50) 
Low risk types
**
 5.41 (1.21, 24.16) 5.90 (1.29, 27.01) 5.10 (1.14, 22.83) 5.79 (1.29, 25.95) 5.56 (1.24, 25.05) 
High risk types** 2.89 (1.38, 6.02) 3.07 (1.46, 6.47) 2.94 (1.40, 6.15) 2.65 (1.26, 5.55) 3.00 (1.42, 6.32) 
      
6 4.61 (0.93, 22.84) 5.23 (1.03, 26.59) 4.41 (0.89, 21.93) 4.66 (0.93, 23.22) 4.69 (0.94, 23.36) 
11 NE NE NE NE NE 
16 4.63 (1.41, 15.23) 6.07 (1.82, 20.19) 4.66 (1.41, 15.35) 4.53 (1.36, 15.04) 5.61 (1.67, 18.87) 
18 NE NE NE NE NE 
31 NE NE NE NE NE 
   33 NE NE NE NE NE 
45 NE NE NE NE NE 
52 15.78 (3.04, 81.92) 15.20 (2.88, 80.20) 18.11 (3.36, 97.11) 15.03 (2.88, 78.30) 17.93 (3.44, 93.43) 
58 19.60 (3.56, 107.79) 25.12 (4.17, 151.46) 20.01 (3.63, 110.89) 20.49 (3.69, 113.70) 24.84 (3.70, 166.78) 
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d 
Adjusted for Race 
e
Adjusted for smoking status as a time varying covariate 
f
Adjusted for alcohol use as a time varying covariate 
g
Adjusted for lifetime female sexual partners as a time varying covariate 
h
Adjusted for number of new female partners in past 6-12 months as a time varying covariate 
i
Adjusted for frequency of sexual intercourse with female partners as a time varying covariate 
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Footnotes: 
Reference group consists of men without a prior genital HPV infection of the same genotype 
*Any type includes infections from any of the nine vaccine type HPVs (6, 11, 16, 18, 31, 33, 45 52 and 58) 
** Low risk types include HPV6 and 11 
*** High risk types include HPV 16, 18, 31, 33, 45, 52, and 5 
 
Appendix E: Table 4.1b: Risk of sequential acquisition of anal human papillomavirus (HPV) infection following a 
genital HPV infection 
 
Smoking 
status 
Alcohol 
use 
Lifetime female 
partners 
New female partners Frequency of 
intercourse 
HPV types 
Adjusted
a
 
HR (95% CI) 
Adjusted
b
 
HR (95% CI) 
Adjusted
c 
HR (95% CI) 
Adjusted
d 
HR (95% CI) 
Adjusted
e 
HR (95% CI) 
All types
*
 2.14 (1.07, 4.29) 2.28 (1.10, 4.72) 2.53 (1.21, 5.29) 5.14 (1.40, 18.82) 5.14 (1.40, 18.82) 
Low risk types
**
 5.74 (1.28, 25.74) 5.16 (1.15, 23.17) 7.80 (1.41, 43.16) NE NE 
High risk types
***
 2.83 (1.35, 5.91) 3.13 (1.43, 6.83) 3.34 (1.53, 7.28) 6.95 (1.91, 25.27) 6.95 (1.91, 25.27) 
      
6 4.84 (0.97, 24.14) 4.66 (0.92, 23.56) 6.19 (1.03, 37.25) NE 5.65 (1.13, 28.24) 
11 NE NE NE NE NE 
16 4.21 (1.27, 13.99) 4.46 (1.34, 14.85) 6.44 (1.91, 21.66) 6.50 (1.06, 39.69) 5.22 (1.55, 17.57) 
18 NE NE NE NE NE 
31 NE NE NE NE NE 
   33 NE NE NE NE NE 
45 NE NE NE NE NE 
52 15.49 (2.97, 80.79) 23.35 (2.57, 211.94) 14.52 (2.77, 76.03) 17.95 (1.33, 242.47) NE 
58 25.39 (4.13, 156.24) 23.50 (4.19, 131.84) 23.56 (3.72, 149.07) 40.54 (4.51, 364.28) 35.70 (5.11, 249.28) 
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aAdjusted for smoking status as a time varying covariate 
bAdjusted for alcohol use as a time varying covariate 
cAdjusted for lifetime female sexual partners as a time varying covariate 
dAdjusted for number of new female partners in past 6-12 months as a time varying covariate 
eAdjusted for frequency of sexual intercourse with female partners as a time varying covariate 
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Appendix F: Institutional Review Board (IRB) approval 
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Appendix G: Institutional Biosafety Committee (IBC) approval 
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Appendix H: Informed consent document:  
Subject’s Name MCC# 13930 
Medical Record # IRB# 102660 
 
Informed Consent to Participate in Research and Authorization to Collect, Use and Share 
Your Health Information Moffitt Cancer Center/University of South Florida Information to 
Consider Before Taking Part in this Research Study 
Researchers at Moffitt Cancer Center (MCC) study many topics. To do this, we need the help of 
people who agree to take part in a research study. Research studies include only people who 
choose to take part. This document is called an informed consent form. Please read this 
information carefully and take your time making your decision. Ask the researcher or study staff 
to discuss this consent form with you. Please ask him/her to explain any words or information 
you do not clearly understand. We encourage you to talk with your family and friends before you 
decide to take part in this research study. The nature of the study, risks, inconveniences, 
discomforts, and other important information about the study are listed below. 
We are asking you to take part in a research study called: Natural History of HPV Infection in 
Men: The HIM Study 
The person who is in charge of this research study is Anna Giuliano, PhD. This person is called 
the Principal Investigator. However, other research staff may be involved and can act on behalf 
of the person in charge. 
The research will be conducted at: 
H. Lee Moffitt Cancer Center & Research Institute, Inc. 
(Moffitt Cancer Center) 
12902 Magnolia Drive 
Tampa, FL 33612 
This research is being sponsored by the National Institutes of Health. 
Why is this research being done? 
The purpose of this study is to learn about the natural history of Human Papillomavirus (HPV) 
infection in men. The study will also find out what factors are linked to HPV in men including 
other sexually transmitted diseases (STDs). If you test positive for syphilis, gonorrhea or 
chlamydia, we are required by law to report the results to the Florida Department of Health. You 
will be able to get free medical treatment from the Florida Department of Health for these STDs. 
You will be given a written report of the results of the STD testing. 
HPV is a virus that is transmitted through sexual intercourse. This virus is common in men and 
women. Some types of this virus can cause warts. Other types of this virus cause changes in the 
cervix or cancer in women. Anal, penile and oropharyngeal (cancer that develops in the part of 
the throat just behind the mouth, called the oropharynx) cancers are very rare cancers associated 
with HPV infections. 
Most people with this virus have no signs of infection. There is no effective treatment against the 
virus yet. In most cases the infection goes away on its own. Little is known about this virus in 
men. Through this study, the researchers hope to learn more about HPV infection in men, so that 
they can develop effective programs to reduce HPV disease burden in men and 
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Medical Record # IRB# 102660 
women. 
The use of condoms may help lessen the chances of spreading HPV and other STDs between 
sexual partners. However if the HPV infection is on skin not covered by the condom, it is 
possible for the disease to spread. 
Why are you being asked to take part? 
We are asking you to take part in this study because you are a man between 18 and 70 years of 
age, live in southern Florida, US; Sao Paulo, Brazil; or the state of Morelos, Mexico. A pilot 
study will be completed consisting of 180 men (about 50 men per year for 3½ years) ages 45 to 
70 who live in southern Florida. You have never been told you have penile or anal cancer or 
genital warts and you are willing to attend scheduled visits every six months in the next 4 years. 
We want to learn about the natural history of Human Papillomavirus (HPV) infection in men, 
including what factors are linked to HPV in men. 
How long will you be asked to stay in the study? 
This study may take up to 5 years to complete; however, you will only be active in this study for 
approximately 4 years. In order for the researchers to learn about the natural history of HPV, the 
study will need to last for 4 years. 
How often will you need to come for study visits? 
A study visit is one you have with the study doctor or study staff. This visit is different than 
visits with your regular doctor. You will need to come for an additional 9 study visits, once every 
6 months for 4 years. Most study visits will take about 45 minutes. Some may be shorter. 
At each visit, the doctor or staff will: 
• Do an exam of the skin on your genitals. The health provider will swab the outside of your 
penis and the anal canal with a wet swab to test for HPV. If visible lesions or warts are present, 
samples will be collected from those areas using a wet swab. You will be told if the health 
provider finds any sores or lesions that need care. 
• Collect an oral cell sample using mouthwash. You will be asked to swish your mouth with 
mouthwash (this is called an oral rinse). The unused oral sample will be frozen and stored at the 
Moffitt Cancer Center in Tampa, FL. You will be asked at the end of this consent if you agree to 
have these samples stored for future testing by the investigators. 
• Collect a blood sample. The clinic staff will use a needle to draw 2-3 tablespoons of blood from 
a vein in your arm. The blood will be tested for HPV antibodies (proteins produced by the body 
as part of its defense against HPV). Once a year, a portion of this blood will also be tested for 
HSV 2 (herpes simplex virus 2). The blood sample collected at your last visit will not be tested 
for HSV2. The blood collected at your second visit will also be tested for syphilis. HSV 2 and 
syphilis are two sexually transmitted infections. The unused blood will be frozen and stored at 
the Moffitt Cancer Center in Tampa, FL. You will be asked at the end of this consent if you 
agree to have 
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these samples stored for future testing by the investigators. Once a year, you will be asked for a 
urine sample. This urine sample will be tested for chlamydia. You will not provide urine at your 
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last visit. The urine sample collected at your second visit will also be tested for gonorrhea. 
Chlamydia and gonorrhea are two sexually transmitted infections. 
• Give you a survey to complete. Because HPV is passed on by skin-to-skin contact, such as 
during sex, you will be asked questions on the survey about your sexual history. For example 
you may be asked about the number of sex partners you have had, and the date of the last sex. 
Some of these questions may be personal or sensitive. You can refuse to answer any question. 
• Complete a Symptom and Medication Review checklist. 
A schedule and sequence of clinic procedures and laboratory specimen collection is attached to 
this consent form. 
How many other people will take part? 
About 1000 men, ages 18-44, will take part in this study in the Tampa Bay area. People will also 
take part at other study sites. A total of about 3000 men will take part. About fifty (50) men per 
year for the next 3½ years, for a total of 180 men ages 45 – 70, will be added as a pilot study. 
Will the treatment you get change if you take part in this study? 
The treatment you now get from your regular doctor will not change if you take part in this 
study. You are free to withdraw from the study at any time without causing bad feelings or 
changing you medical care. 
What other choices do you have if you decide not to take part? 
If you decide not to take part in this study, that is okay. This choice will not affect your usual 
health care. There is no cure for HPV infection in men; however there are options for treating 
visible warts, however new warts may appear during treatment. Treatment options include; 
application of therapeutic agents such as bichlor- or trichloracetic acid, podophyllum, or 
imiquimod, cryotherapy (freezing), laser therapy, or excision (surgical removal). 
How do you get started? 
If you decide to take part in this study, you will need to sign this consent form. Because the study 
needs to enroll men who can return for 9 more visits, study staff will ask for your complete 
contact information. This is needed in order to send reminders about your appointments. 
At the end of the visit the study staff will schedule your next clinic visit. You will be given 
instructions for the next visit: no sex 24 hours before the visit, no washing of genitals with soap 
the morning of the visit. All these steps are necessary to allow for detection of HPV. 
The study staff will contact you to remind you of the next appointment by sending a reminder 
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letter two weeks prior to the appointment or an e-mail one week before the appointment, 
whichever is your choice of contact. In addition, the study staff will contact you the day prior to 
the appointment date. If you wish to withdraw from the study, you should tell the staff so they 
will not continue to contact you. 
What will happen during this study? 
At each visit, the health provider will do an exam of the skin on your genitals. The provider will 
swab the outside of your penis with a wet swab to test for HPV. If visible lesions or warts are 
present, samples will be collected from those areas using a wet swab. You will be told if the 
health provider finds any sores or lesions that need care. If during visual physical examination, 
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genital warts are detected, the clinician can refer you to an outside clinic for treatment and follow 
up. Prescription may be written for topical cream. If we discover lesions that look like they may 
be the kind of lesions that could turn into cancer, we will refer you for an evaluation at Moffitt 
Cancer Center. This evaluation will be free. 
You will be asked to give an oral cell sample using mouthwash at each visit. A subset of the 
study participants (200 men) will also be asked to provide 2 oral samples on the same day for 
one visit only. You will also be asked to give a blood sample at each visit. The clinic staff will 
use a clean needle to draw 2-3 tablespoons of blood from a vein in your arm. The blood will be 
tested for HPV antibodies. Once a year, a portion of this blood will also be tested for HSV 2 
(herpes simplex virus 2). The blood collected at your second visit will also be tested for syphilis. 
Once a year, you will be asked to give a urine sample that will be tested for chlamydia. The urine 
sample collected at your second visit will also be tested for gonorrhea. 
If you have a biopsy of an external genital wart/lesion, you will be asked to give a blood sample 
during the biopsy visit. The clinic staff will use a clean needle to draw about 1 tablespoon of 
blood from a vein in your arm. The blood will be used for ADCC (antibody-dependent cellular 
cytotoxicity) testing. ADCC testing is a new test to test for HPV antibodies (proteins produced 
by the body as part of its defense against HPV). Even if you are not having a biopsy, we might 
ask you to donate 1 tablespoon of blood for ADCC testing so that we can compare the blood 
samples. 
You will be given a questionnaire to complete at each visit. Because HPV is passed on by skin-
to-skin contact, such as during sex, you will be asked questions on the survey about your sexual 
history. For example you may be asked about the number of sex partners you have had, and the 
date you last had sex. Some of these questions may be personal or sensitive. You can refuse to 
answer any question. 
In addition to the questionnaire above, you will be asked to complete a medical history 
questionnaire, a physical activity questionnaire, a food frequency questionnaire, and a symptom 
and medication review checklist during your clinic visits. A schedule and sequence of clinic 
procedures, questionnaires and laboratory specimen collection is attached to this consent form. 
Results of HPV testing 
The test for human papillomavirus (HPV) being used in this study is a research test and will 
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include the 37 HPV types most commonly found in the genital area. 
• There is no FDA licensed test for HPV detection in men. 
• You will receive your results in approximately 6 months. 
• You will receive the HPV results from the study clinician, starting at visit 3. The clinician does 
not have access to the specific HPV type, but you will be told if you are positive or negative for 
any of the 37 types. 
• You will not receive the results from the oral cell sample collection. 
Will you be paid for taking part in this study? 
We will pay you for the time you volunteer in this study. 
• You will get a total of $540 to be part of this study. You will get paid for each completed visit. 
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• The payment will be as follows: Baseline Visit (Visit 1): $50, Visit 2: $75, Visit: 3: $40, Visit 
4: $40, Visit 5: $50, Visit 6: $75, Visit 7: $40, Visit 8: $50, Visit 9: $40, Visit 10: $80. 
Will it cost anything to be in this study? 
It will not cost you anything to take part in the study. 
You will not have to pay for study tests or procedures in this study. 
Your insurance plan will not have to pay for any study costs. 
What are the potential benefits if you take part in this study? 
We don’t know if you will get any health benefits by taking part in this study. There may be a 
benefit to researchers who need to know the natural history of HPV in men to develop methods 
to prevent infection and to slow or halt its progress to disease. Future studies may help 
researchers know how HPV is passed on and how long men have the infection. In addition to 
HPV testing you will also be tested for chlamydia, syphilis, herpes simplex virus 2 and 
gonorrhea free of charge. 
What are the risks if you take part in this study? 
The questions you are asked are personal and sensitive and may cause you to feel shame or 
worry. You can refuse to answer any questions. You can refuse to be part of the study at any 
time. 
When blood is drawn, you may feel some pain and you may faint or feel faint. After blood is 
collected, you may have a bruise or pain and a slight risk of infection at the site where the blood 
was taken. Rubbing the penis with a wet swab, and giving a urine sample will not cause you 
pain, but it may cause some shame or social discomfort. There are no risks to giving an oral cell 
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Many people have HPV. Most infections clear on their own. You will not need to make changes 
in your health care or the health care of your partner. The use of condoms may help lessen the 
chances of HPV spreading between sexual partners. However if the HPV infection is on skin not 
covered by the condom, it is possible for the disease to spread. Your female partner(s) should 
have regular Pap smears regardless of your HPV status. 
Risks of undetected HPV in female partners 
Some types of the HPV virus that can be transmitted between sexual partners cause changes in 
the cervix in women. To detect these changes in the cervix, your female partner should get a 
yearly pap smear. We advise you to talk to your female partner about getting a yearly pap smear 
no matter what your HPV test results are. 
Moffitt Cancer Center Injury Statement 
If you believe you have been injured as a result of your participation in this study or if you have 
questions about your rights as a person who is taking part in a research study, you may call the 
Moffitt Cancer Center Risk Manager at 813-745-4219. Florida law (Statute 768.28) limits the 
liability of Moffitt Cancer Center. Moffitt Cancer Center cannot pay for lost wages, disability, or 
discomfort. A copy of this statute is available upon request at 813-745-1869. This statute 
provides that damages are available only to the extent that negligent conduct of a Moffitt Cancer 
Center employee caused your injuries. The damages available in this situation are limited by law. 
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The Moffitt Cancer Center and investigators have made no provision for monetary compensation 
in the event of physical illness or injury resulting from this study. 
Be aware that your health care payer/insurer might not cover the costs of study-related injuries or 
illnesses. 
The use and disclosure of your personal health information 
We understand that information about you and your health is personal, and we are committed to 
protecting the privacy of that information. Because of this commitment, we must obtain your 
written authorization before we use or disclose your information for this study. 
Research at the Moffitt Cancer Center may be undertaken jointly with the University of South 
Florida or other persons or entities under an organized health care arrangement. By signing this 
form you are permitting researchers at Moffitt Cancer Center to use personal health information 
for research purposes within its organized health care arrangements. You are also allowing the 
Moffitt Cancer Center to disclose your personal health information to outside organizations or 
individuals that participate in this study. We may publish what we find out from this study. If we 
do, we will not let anyone know your name. We will not publish anything that would let people 
know who you are. 
If you do not agree to the use and disclosure described above, you cannot be in the study. 
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Who will disclose, receive, and/or use your information? 
Federal law says we must keep your study records private. We will keep the records of this study 
private by keeping them in a locked area or on a secure computer. The survey will be marked 
with a code and not your name. If you give your permission to be contacted, the study staff will 
not identify the nature of participation. Samples and data sent to the Moffitt Cancer Center and 
Johns Hopkins University will only be marked with codes. The study staff will keep the 
codebook that links your name to the code number in a locked file. The consent forms, test 
results and survey will be kept in locked areas. To do this research, the following people and/or 
organization(s) will be allowed to disclose, use, and receive your information, but they may only 
use and disclose the information to the other parties on this list, to you or your personal 
representative, or as permitted by law: 
• Every research site for this study, including the Moffitt Cancer Center, and each site’s study 
team, research staff and medical staff; 
• Any person who provides services or oversight responsibilities in connection with this study; 
• Every member of the Moffitt Cancer Center workforce who provides services in connection 
with this study; 
• The person who is responsible for the study nationwide or worldwide (study chairperson); 
• Any laboratories and other individuals and organizations that use your health information in 
connection with this study; 
• Any sponsor of the study, including the following sponsors: National Institutes of Health 
• Any federal, state or local governmental agency that regulates the study (such as the FDA, 
Florida Department of Health (FDH), the U.S. Department of Health & Human Services 
(DHHS), and the Office for Human Research Protections (OHRP)); 
• Other government agencies in this or other countries; 
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• The designated Protocol Review and Monitoring Committees, Institutional Review Boards, 
Privacy Boards, Data and Safety Monitoring Board and their related staff that have oversight 
responsibilities for this study; 
• The National Cancer Institute in evaluating the ongoing research of the Moffitt Cancer Center 
as a Comprehensive Cancer Center. 
The organizations and people listed above may employ or pay various consultants and 
companies to help them understand, analyze and conduct this study. All of these people may not 
be known now, but if you would like to have more specific information about this at any time 
during the study, you may ask the study doctor and your questions will be answered. 
Moffitt Cancer Center cannot guarantee the privacy of your information, or block further use or 
distribution, after the information has left the Moffitt Cancer Center. Others listed above may 
further disclose your information, and may no longer be covered by federal privacy regulations. 
If all information that does or can identify you is removed from your records, the remaining 
information will no longer be subject to this authorization and may be used or shared for other 
purposes. 
You might have the right to see and copy your health records related to this research. You 
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might not be able to see or copy some of your records until after all participants finish the study. 
If it is necessary for your care, your records will be provided to you or your regular doctor. 
What information will be used or disclosed? 
By signing below, you authorize the use and disclosure of your entire study record and any 
medical or other records held by Moffitt Cancer Center, including, but not limited to, HIV/AIDS, 
mental health, substance abuse or genetic information. The purpose for the uses and disclosures 
you are authorizing is to conduct the study explained to you during the informed consent and 
research authorization process and to ensure that the information relating to that study is 
available to all parties who may need it for research purposes. 
Your authorization to use your health information will never expire unless and until you 
expressly revoke it in writing to the investigator on the first page of this form. If you revoke your 
authorization, you will not be able to continue in the study. 
By signing this form, you authorize the use and/or disclosure of your protected health 
information described above. Your information may also be used as necessary for your research-
related treatment, to collect payment for your research-related treatment (when applicable), and 
to run the business operations of the Moffitt Cancer Center. 
Any data collected prior to your letter will continue to be used as necessary to preserve the 
integrity of the study, however no additional information will be collected after you withdraw 
your authorization. 
You will receive a signed copy of this form. 
What happens if you decide not to take part in this study? 
You should only take part in this study if you want to volunteer. You should not feel that there is 
any pressure to take part in the study, to please the investigator or the research staff. You are free 
to participate in this research or withdraw at any time. There will be no penalty or loss of 
benefits you are entitled to receive if you stop taking part in this study. 
What if you join the study and then later decide you want to stop? 
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If you decide you want to stop taking part in the study, tell the study staff as soon as you can. 
If for some unplanned reason you move from the area during the study, you agree to tell the 
study staff as soon as you know you are moving. 
It is important to understand that you may leave the study at any time. It is important to let the 
study staff know if you will not be able to keep an appointment or leave the study. 
New information about the study 
During the course of this study, we may find more information that could be important to you. 
This includes information that, once learned, might cause you to change your mind about 
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being in the study. We will notify you as soon as possible if such information becomes available. 
Where can you get the answers to your questions, concerns, or complaints? 
If you have any questions, concerns or complaints about this study, or experience an adverse 
event or unanticipated problem, call Dr. Anna Giuliano at (813) 745-6820. 
If you have questions about your rights as a research patient at Moffitt Cancer Center, call the 
Corporate Compliance Department at The Moffitt Cancer Center at (813) 745-1869. 
If you have questions about your rights as a participant in this study, general questions, or have 
complaints, concerns or issues you want to discuss with someone outside the research, call the 
USF IRB at (813) 974-5638. 
Consent to Take Part in this Research Study and Authorization to Collect, Use and Share 
Your Health Information 
It is up to you to decide whether you want to take part in this study. If you want to take part, 
please sign the form, if the following statements are true. A representative of the Moffitt Cancer 
Center must answer your questions completely before providing this form to you. You or your 
personal representative should read this form and understand it before signing below. 
I freely give my consent to take part in this study and authorize that my health information 
as agreed above, be collected/disclosed in this study. I understand that by signing this form I 
am agreeing to take part in research. I have received a signed copy of this form to take with me. 
Signature of Person Taking Part in Study Date 
Printed Name of Person Taking Part in Study 
Statement of Person Obtaining Informed Consent / Research Authorization 
I attest that the participant named above had enough time to consider this information, had an 
opportunity to ask questions, and voluntarily agreed to be in this study. 
Signature of Person Obtaining Informed Consent / Research Authorization Date 
Printed Name of Person Obtaining Informed Consent / Research Authorization 
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Permission to perform Anal Canal Sampling As part of this study, we would like to test for HPV 
that may be in your anal canal. In order to get a sample of cells from your anal canal, the 
clinician will use a swab moistened with normal saline (salt water) to swab the anal canal. The 
swab will be gently inserted into the anus and turned around while inside the anus. 
You do not have to agree to this test to take part in the rest of the study. 
Please initial one of the lines below: 
____ I agree to anal canal sampling. 
____ I DO NOT agree to anal canal sampling. 
Permission to store specimens 
You are being asked to give permission for your remaining samples to be stored in a specimen 
bank for future use at the Moffitt Cancer Center and other collaborating institutions. They will be 
stored without any personal information that could link them to you. The samples will have a 
code. The study staff will have the codes linking you to the samples stored in a locked, private 
area. Samples may be used for evaluation of infectious diseases or immune markers of infection. 
The results of this testing would not be available to you or your physician, and would not alter 
your care in any manner. If a researcher wishes to use these specimens in a future study, they 
would need to submit a research proposal to the University of South Florida Human Subjects 
Committee who will act on your behalf to weigh the risks and benefits of future testing of your 
specimens, and whether the results can be linked to the coded questionnaire data from this study. 
You can choose not to have your specimens stored, and still be part of this study. Also, at any 
time you may change your mind and decide that you do not want to have your samples stored. In 
that case you must contact Dr. Anna Giuliano at (813) 745-6820 who will ensure that your 
samples are destroyed. 
Please initial one of the lines below: 
____ I agree for my remaining samples to be stored and used for future research studies. 
____ I DO NOT agree for my remaining samples to be stored and used for future research 
studies. 
Permission to be contacted for future studies 
You are being asked if you give your permission to be contacted for future studies conducted by 
Dr. Giuliano at the Moffitt Cancer Center. 
Please initial one of the lines below: 
____ I agree to be contacted for future studies. 
____ I DO NOT agree to be contacted for future studies. 
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